

6th Edition

NEMLIST

NAMIBIA ESSENTIAL MEDICINES LIST

REPUBLIC OF NAMIBIA



MINISTRY OF HEALTH AND
SOCIAL SERVICES

NEMLIST
SIXTH EDITION - FEBRUARY 2016

MINISTRY OF HEALTH AND SOCIAL SERVICES



NEMLIST

NAMIBIA ESSENTIAL MEDICINES LIST

Sixth Edition / February 2016



Essential Medicines List Secretariat

Division: Pharmaceutical Services

Ministry of Health and Social Services

Private Bag 13198, Windhoek

Tel.: 061 203 2344

Fax: 061 234 136

Email: reception@nmpc.com.na



Foreword



The World Health Organisation (WHO) produced the first model Essential Medicines list in 1977 after the Essential Medicine and the National Medicines Policy concepts had been introduced by the World Health Assembly of 1975. At Independence, Namibia's Ministry of Health and Social Services adopted the Primary Health Care approach which identifies the Essential Medicine concept as a key element in meeting the healthcare needs of the population. The Essential Medicines Concept involves developing a list of 'Essential Medicines' which are those medicines that satisfy the healthcare needs of the majority of the population and must be available at all times, in adequate amounts and in the appropriate dosage form.

The first Namibia Essential Medicine list known as the Namibia Essential Drug List (Nedlist) was launched and published in 1995. The 2nd edition of the Nedlist was published in 1999. The 3rd edition was published in December 2003 and was renamed the Namibia Essential Medicines List (Nemlist) followed by the 4th edition in December 2008 and the 5th edition in May 2012. The 5th edition of the Nemlist also included recommendations of the 15th and 17th WHO Model Essential List committee meetings which had recommended changes to the WHO model essential medicine list. The 6th Edition of Nemlist includes recommendations from two EMLC meetings held on 26th March 2014 and 17th September 2015 and also includes some recommendations made by the WHO Expert Committee on the Selection and Use of Essential Medicines during their 19th and 20th committee meetings.

The Nemlist acts as a guide for the level of availability and use of essential medicines based on the skills levels of health workers as well as availability of diagnostic facilities at the various levels of the Namibian public sector healthcare system. Some medicines are available at all levels of care while others are restricted to high level institutions or use only by specialist cadres. The Nemlist is reviewed regularly, based on motivations for changes received from programs and users at health facilities. Additionally, the Nemlist revisions will also be made in line with the newly published Namibia Standard Treatment Guidelines (STGs). These two documents complement each other and should be used together to ensure that medicines are used rationally. The form for requesting for changes to the Nemlist has been modified to include requests for changes to the Namibia Standard Treatment Guidelines (STGs) on the same form.

I wish to urge all health workers to familiarize themselves with the procedures and tools for motivating for changes to the Nemlist. I would also like to encourage all the users of the document, through their Therapeutics Committees to actively contribute to the review of the Nemlist and Namibia Standard Treatment Guidelines (STGs) by sending fully researched applications for changes to the EMLC. Your participation and contribution to the review of the Nemlist and STGs is important if we are to have guidelines that are up to date, reflect current medical practices and contain medicines that meet the needs of the Namibian public.

It is my hope that health workers will continue to use the Nemlist and also accept the new STGs as national, evidence-based consensus documents which will assist and guide all of us in continuing to render quality health services to our people.



Dr. Bernhard Haufiku
Minister of Health & Social Services



Preface

The first edition of the Namibia Essential Medicines List (Nemlist), then known as the Namibia Essential Drugs List (Nedlist), was published in May 1995 with subsequent editions printed in May 1999, March 2003 and December 2008 and May 2012. The Nemlist has served as a useful tool for healthcare workers in guiding their management and use of medicines. The Central Medical Store is also guided by the Nemlist in procurement and distribution of medicines to public health facilities.

The field of medicine is characterised by rapid changes. These include: the emergence of new diseases of public health importance, the development of new medicines with better safety or efficacy than the older ones, development of resistance to commonly used antimicrobial agents and decreased cost of medicines whose patents have expired hence allowing production of more competitively priced generics formulations.


Changes in the field of medicine necessitate regular revision of the Nemlist. Motivations or applications for changes are received by the Essential Medicines List Committee's (EMLC) secretariat from health workers all over the country. The EMLC, comprising medical doctors, pharmacists, nurses and other relevant professionals, evaluates the motivations submitted and forwards recommendations for final approval to the Ministry's Policy, Management Development and Review Committee (PMDRC).

The approved Nemlist details all the medicines which can be ordered, stored and prescribed at public sector health facilities according to level of care. The Ministry's Central Medical Store is tasked to ensure availability of these medicines by procuring quality products at the lowest possible cost from various suppliers.

The 6th edition of the Nemlist consists of four main parts. The first chapter explains how to use the document and how to handle exceptional situations. The second chapter provides details on the two categories of medicines under Special Use Classification: Restricted Use (R) and Integrated Management of Adult and Adolescent Illnesses - restricted (IMAI-R). These two categories contain items that are to be used only in certain specific conditions, and require close control and monitoring by both pharmacy and prescribing staff to avoid inappropriate use. The third chapter lists the essential medicines according to their therapeutic categories, and the last chapter contains an alphabetical list of all items for easy reference.

The annexes include the form to be used to request changes to the Nemlist and /or STGs. This form facilitates rationalisation of analysis and decision making within the EMLC. Also included in the annexes are standard operating procedures (SOPs) for submitting applications for changes to the Nemlist and for procuring non-Nemlist medicines if required at the facilities. A summary of the procedures for the technical evaluation of applications by the EMLC is also attached.

I would like to thank the EMLC members, co-opted members as well as all individuals who contributed to this revised edition of the Nemlist by sending motivations to the Secretariat.



Dr. Andreas Mwoombola
Permanent Secretary

Essential Medicines List Committee (EMLC) 2014

Chairperson

1	Dr Norbert Forster	Deputy Permanent Secretary, MoHSS
---	--------------------	-----------------------------------

EMLC Members

2	Ms. Lazarus Indongo	Deputy Director, Ph Ss ¹
3	Mr Kennedy Kambyambya	Chief Pharmacist, NMPC
4	Ms A Mwandinohamba	Deputy Director, Directorate of Special Programmes
5	Ms. Juliet Bulemela	Regional Pharmacist, <i>Ohangwena</i>
6	Ms Rauna Shitaleni	Regional Pharmacist, <i>Oshikoto</i>
7	Dr Simon Ikandi	Chief Medical Officer, <i>Omaheke</i>
8	Dr LL Ndaningina	Acting PMO, Katutura Health Centre
9	Mr. Thomas Mbeli	Deputy Director: PP & HRD ² (Health Economist)
10	Dr Assegid Mengistu	Advisor, TIPC ³

EMLC Secretariat

11	Mr Emanuel Ugburo	Pharmacist: NMPC
12	Bayobuya Phulu	STA-MSH/SIAPS

Essential Medicines List Committee (EMLC) 2015

Chairperson

1	Dr Norbert Forster	Deputy Permanent Secretary, MoHSS
---	--------------------	-----------------------------------

Deputy Chairperson

2	Ms. Lazarus Indongo	Deputy Director, Ph Ss
---	---------------------	------------------------

EMLC Members

3	Mr Kennedy Kambyambya	Chief Pharmacist, NMPC
4	Dr. Ndapewa Hamunime	CMO : HIV /AIDS and STI Control Programmes
5	Mr. Ahmad Zaman	Regional Pharmacist, Kunene
6	Ms Rauna Shitaleni	Regional Pharmacist, Oshikoto
7	Dr Simon Ikandi	Chief Medical Officer, Omaheke
8	Dr L Ndaningina	Chief Medical Officer, Khomas
9	Mr. Thomas Mbeeli	(Deputy Director: PP & HRD ⁴ (Health Economist
10	Dr Assegid Mengistu	TIPC Medical Officer
11	Mr. Tonata Ngulu	Acting Chief Pharmacist: Central Medical Store
12	Mr. Yousef Makar	Chief Pharmacist: Windhoek Central Hospital

EMLC Secretariat

13	Mr. Qamar Niaz	Senior Pharmacist ; NMPC
14	Bayobuya Phulu	STA-MSH/SIAPS
15	Naita Nghishekwa	Chief Pharmacist, NMPC

¹Ph Ss = Pharmaceutical Services

²PP & HRD = Policy Planning & Human Resource Development

³TIPC = Therapeutics Information & Pharmacovigilance Centre



List of Abbreviations

AIDS	Acquired Immuno-deficiency Syndrome
ATC	Anatomical Therapeutic Chemical (classification)
ARV	Antiretroviral Medicine
CMS	Central Medical Stores
EMLC	Essential Medicines List Committee
HIV	Human Immuno-deficiency Virus
IMAI	Integrated Management of Adult & Adolescent Illness
MDI	Metered Dose Inhaler
MoHSS	Ministry of Health & Social Services
Nemlist	Namibia Essential Medicines List
PEP	Post Exposure Prophylaxis
PMCT	Prevention of Mother to Child Transmission
SOP	Standard Operating Procedure
STGs	Standard Treatment Guidelines
STI	Sexually Transmitted Infections

Table of Contents

Foreword.....	i
Preface.....	ii
List of Abbreviations.....	iv
Table of Contents	v
1. How to use the Sixth Edition of the Namibia Essential Medicines List	1
1.1. <i>General</i>	1
1.2. <i>Structure and Layout</i>	3
1.3. <i>Ordering items on the Nemlist</i>	5
1.4. <i>Purchase of medicines not included in the Nemlist</i>	6
1.5. <i>Feedback and requests for changes to the Nemlist</i>	6
2. Restricted Use Items	6
2.1. <i>IMAI-R use items</i>	6
2.2. <i>Restricted (R) items</i>	7
2.3. <i>General Control Measures for All Restricted Use (R) Items</i>	7
2.4. <i>Specific Control Measures for Individual Restricted Use Items</i>	7
3. The Namibia Essential Medicines List - organised according to the main therapeutic groups	13
4. The Namibia Essential Medicines List - Alphabetic Index	41
5. Annexes	61
5.1. Annex 1: Guidelines for requesting and evaluating applications for changes to the Nemlist or buy-outs items.....	61
5.2. Annex 2: Summary of the technical guidelines for evaluating requests for changes to the Nemlist.....	66
5.3. Annex 3: Instructions for submitting changes to the Nemlist	69
5.4. Annex 4: Request form for changes to the Nemlist.....	72
5.5. Annex 5: Instructions for requesting procurement of a Non-Nemlist medicine (Buy-out).....	77
5.6. Annex 6: Application form for buy-out	79





1. How to use the *sixth* Edition of the Namibia Essential Medicines List

1.1. General

The sixth edition of the Namibia Essential Medicines List (Nemlist) contains pharmaceutical products that have been selected as essential for the Ministry of Health and Social Services to deliver high quality pharmaceutical services to the population of the Republic of Namibia at an affordable cost. They are considered adequate to treat the majority of public health conditions prevailing in Namibia.

Changes in morbidity, clinical practice and internationally accepted treatment standards as well as practical experiences in our health institutions have all necessitated the production of this edition of the Nemlist. Requests for changes to the Nemlist were received from various health institutions within Namibia, and decisions regarding the requests were made based on the criteria laid down in the National Medicines Policy for Namibia.

Aluminium Hydroxide + Magnesium Hydroxide Oral Suspension was deleted from the Nemlist following the EMLC meeting on 26th March 2014 as it was part of a list of medicines deleted from the WHO Essential Medicines List (EML) due to lack of evidence of efficacy.

Tuberculin TINE test was deleted after consideration of motivations from the Namibia TB Program.

No items were deleted in EMLC meeting held on 17th September 2015.

Nineteen items were added to the list during EMLC meeting held on 26th March 2014;

1. Amoxicillin + Clavulanic acid 875/125mg Tablets
2. Amoxicillin + Clavulanic acid 125/31 mg suspension
3. Amoxicillin + Clavulanic acid 125/31 mg Injection
4. Misoprostol 200mcg Tablets
5. Total phospholids/ surfactant 25 mg/ml
6. Sterile Water 3 litres for irrigation
7. Sodium Chloride 0.9% 3 litres for irrigations
8. Therapeutic Complex of Minerals and Vitamins (CMV)
9. Ready to Use Therapeutic Food (RUTF) Plumpy Nut Sachet 92g (500kcal)
10. Ready to Use Supplementary Therapeutic Food 92g (500kcal)
11. Tenofovir + Emtricitabine + Efavirenz 300mg/200mg/600mg (FDC) tablets
12. Tenofovir + Emtricitabine 300mg/200mg (FDC) tablet
13. Lamivudine 30mg + Zidovudine 60mg syrup
14. Lamivudine 30mg + Abacavir 60mg syrup
15. Lamivudine 30mg + Zidovudine 60mg+ Nevirapine 50mg Tablets
16. Lopinavir 100mg + Ritonavir 25mg Tablets
17. Abacavir 60mg tablets
18. Salbutamol injection 500mcg/ml
19. Aluminium hydroxide + magnesium hydroxide suspension 300mg/5ml

Thirty-nine items were added to the list during EMLC meeting held on 17th September 2015;

1. Chondroitin Sulphate 40mg/ml + Sodium Hyaluronate 30mg/ml Ophthalmic viscid surgical device
2. Fusidic acid 10mg /g ophthalmic ointment
3. Olanzapine 10 mg tablets

4. Risperidone 1mg tablets
5. Risperidone 2mg tablets
6. Valproate, sodium 333mg + valproic acid 145 mg Controlled Release Tablets
7. Biperiden 5mg/ml injections
8. Acitretin 25mg Tablets
9. Isotretinoin 20mg capsule
10. Calcipotriol 50mcg + Betamethasone Dipropionate 0.5 mg/g ointment
11. Celecoxib 100mg Capsules
12. Celecoxib 200mg Capsules
13. Paracetamol 500mg/50ml IV infusion
14. Paracetamol 1g/100ml IV infusion
15. Ciprofloxacin 2mg/ml IV infusion
16. Linezolid (2mg/ml) 600mg/300ml IV infusion
17. Linezolid 400mg Tablets
18. Linezolid 600mg Tablets
19. Hydroxychloroquine tablet
20. Voriconazole 200mg/ml vial powder for solution for infusion
21. Vancomycin 500mg powder for injection
22. Vancomycin 1g powder for injection
23. Meropenem 500mg injection
24. Meropenem 1g injection
25. Moxifloxacin 400mg/250ml IV infusions
26. Moxifloxacin 400mg Tablets
27. Delamanid 50mg Tablets
28. Bedaquiline 100mg Tablets
29. Semi Elemental Adult Feeds (ready to hang) e.g. Peptamen Neutral Dual.
30. Semi -elemental Paediatric Feeds (ready to hang) e.g. Peptamen Junior advance Neutral Dual
31. Polymeric Adult Feeds (ready to hang) e.g. Fresubin Original)
32. Polymeric paediatric Feeds (ready to hang) e.g. Nutren Junior ready to drink)
33. Special Immune Modulating Adult Feeds (ready to hang) e.g. Impact entral neutral dual
34. Premature Infants Formulae (ready to drink) e.g. Pre-NAN
35. Diabetic Specific Adult Tube Feed e.g. Diben
36. Specialized Pharmaco-nutrients e.g. Intestamin
37. Esomeprazole 40mg/5ml injection
38. Omeprazole 20mg Capsules
39. Cetirizine 10mg tablets

Twelve items were re-classified during EMLC meeting held on 26th March 2014;

1. Furosemide 40mg tablets
2. Perindopril 4mg tablets
3. Ringers lactate 1 litre
4. Rabies vaccine
5. Diclofenac 50mg injection
6. Magnesium sulphate 500mg/ml injection
7. Fluconazole 2mg/ml injection
8. Prednisolone 10% eye drops
9. Gentamycin 0.3% eye drops
10. Ofloxacin 0.3% eye drops
11. Sodium cromoglycate drops 2% eye drops
12. Dexamethasone + Neomycin + polymixin B [0.1% + 3,500u/ml + 600u/ml] eye drops

One item was re-classified during EMLC meeting held on 17th September 2015;

1. Bimatoprost 0.3mg/ml + timolol 5 mg/ml eye drops

Requests for addition of thirty other items to the Nemlist were not accepted by the EMLC in their meeting on 26th March 2014 and four items during EMLC meeting held on 17th September 2015 for a variety of reasons including supply chain considerations and existence of other suitable agents with better comparative safety or efficacy.

Only those medicines included in the Nemlist will be available to public sector health facilities according to the specified level of care. The Central Medical Store (CMS) will only procure and distribute medicines listed on the Nemlist. Each health worker is therefore requested to thoroughly study this document before prescribing and / or ordering medicines.

1.2. Structure and Layout

The 6th edition Nemlist is divided into four chapters and six annexes.

Chapter 1 gives an introduction to the sixth edition of the Nemlist. Chapter 2 gives details about the restricted Nemlist Classifications – Restricted Use (R) and IMAI-R, as well as details of control measures to be implemented for R and IMAI-R class medicines.

Chapter 3 contains the main body of the Nemlist. The list is arranged broadly in fourteen main sections according to the international Anatomical Therapeutic Chemical (ATC) classification system to enable users to identify the required items in the appropriate category, and to allow for qualitative analysis of medicine use patterns according to types of medicines. The specific ATC codes, however, are not included because they are of no practical use for health workers.

Chapter 4 contains an alphabetical list of all essential medicines for easier reference.

Medicines on the Nemlist are listed according to their generic names

The medicines in the Nemlist are further described in 6 columns:

1st Column: CMS

This column refers to the CMS catalogue number. The numbers printed in this column are the first three figures of the corresponding CMS catalogue number, e.g. 031 means that the full CMS catalogue number of this item starts with 031. This makes it easy to find a particular essential medicine in the order books, which are organised according to catalogue numbers.

2nd Column: Medicine

This column contains the generic names of the medicines, e.g. Diazepam.

- If a preparation contains more than one active ingredient these are separated by a + sign, e.g. Amiloride + Hydrochlorothiazide.
- If more than one generic name is used for a particular preparation the second generic name is indicated in brackets, e.g. Alimemazine (**Trimepazine**).

3rd Column: Strength

This column contains the strength of the preparations.

- If a preparation is available in different strengths, these are listed separately. Diazepam, **2mg** tablets and Diazepam **5mg** tablets appear in 2 separate rows
- The strength of injections is expressed in mg/ml. If ampoules of defined volume are available this is indicated in brackets in the 4th column. For example: Diazepam, **5mg/ml**, injection (**2ml**).
- The strength of powders for injection is expressed in mg/vial, e.g. Cloxacillin, **500mg**, powder for injection.
- For combination products the strength of each component is expressed separated by a + sign e.g. Amiloride + Hydrochlorothiazide, **5mg + 50mg**, tablets.

4th Column: Dosage Form

This column describes the dosage form in which the medicines are available, e.g. tablets.

- Medicines which are available in different dosage forms (e.g. tablets and syrup) are listed in different rows

5th Column: Class

This column describes at which level of care the medicine can be ordered and prescribed

<u>ABC</u>	The preparation can be ordered and prescribed at all levels of care by any competent prescriber.
<u>ABC#</u>	The treatment must be initiated by a Medical Officer, but the preparation can be available at health centres and clinics for follow-up treatment of chronic patients only.
<u>ABC-R</u>	The preparation will be available at PHC facilities to be used ONLY according to conditions specified in the Nemlist. The inventory of these medicines must be controlled with the appropriate registers
<u>AB</u>	The preparation will be available for prescription by any Medical Officer and for ordering at district hospital (Class C) or higher levels
<u>AB*</u>	As for AB but the preparation will also be available at clinics and health centres conducting deliveries.
<u>A</u>	The preparation will be available for ordering and prescription at regional hospitals (Class B) or higher levels
<u>S</u>	The preparation will be available for prescription by designated Specialists only
<u>R</u>	The preparation will be available for use ONLY for specific conditions and/or in restricted circumstances, as specified in Chapter 2 of this document.

<u>IMAI-R</u>	These items are to be made available at clinics and health centres that have staff that have been trained in IMAI. Refer to Chapter 2 for more details They can also be stocked at District Hospital levels and above, and used as normal AB class items in these facilities
---------------	--

6th Column: VEN

The VEN classification describes the various medicines according to the importance of their therapeutic effects. It serves as a guideline to prioritise medicine ordering in cases where budgets are insufficient to keep all Nemlist medicines in stock.

<u>V</u>	These medicines are considered Vital and should be in stock at the respective levels at all times
<u>E</u>	These medicines are Essential for the health services. If at all possible they should be available at the health facilities
<u>N</u>	These medicines are Necessary. If they are not available for prescribing, however, no serious negative impact on the populations' health is expected. In times of budgetary constraints these medicines are of least priority

The VEN classification as presented in the Nemlist is the result of the consultation of all regional directorates and management teams, and the major referral hospitals.

1.3. Ordering items on the Nemlist

Each health facility should only order items that are appropriate for its level of care, i.e. the medicine must be classified for use at the health facility's level. For example a clinic should only order ABC items and a district hospital only ABC and AB items.

On the other hand, only those medicines actually used at a health facility should be kept in stock. For example, a particular clinic should only stock those ABC medicines which are actually used at that facility.

For the purpose of the Nemlist; health centres (Class D hospitals) are considered together with clinics (Class E and F hospitals). However, since some health centres are better equipped and staffed than others (e.g. where medical officers are stationed), the regional director may authorise a particular health centre to order additional items from the AB class of the Nemlist. Such authorisation must be in writing, specify the items which the health centre is authorised to order, and be attached to any order for the specified items.

District hospitals or health centres requiring class A or S items should contact their regional pharmacist. Authorised supplies can then be organised through the regional hospital. If that is not possible, CMS may be authorised by the regional team to supply the specified medicines directly to the district hospital concerned.

Regional pharmacists may keep limited stock of class S items that are appropriate for the conditions in their regions. These stocks must be considered as special stocks for use in emergency situations where alternative first line therapies have failed, and for follow-up treatment of patients in the region. **Records must be kept on the usage of all such items and that usage should be included in the annual report on expenditure.**



1.4. Purchase of medicines not included in the Nemlist

Requests for items that are not contained in the Nemlist must be directed to the institutional or regional therapeutics committee secretariat (or regional pharmacist) for a committee decision and approval by the regional director or medical superintendent, before a buy-out can be requested.

In order to monitor the buy-out situation supervising pharmacists are required to report the requests to the Deputy Director: Pharmaceutical Services, including the motivation for each request.

1.5. Feedback and requests for changes to the Nemlist

Comments on and requests for changes to the Nemlist and/ or the Standard Treatment Guidelines (STGs) should be discussed in institutional therapeutics committees and forwarded with recommendations to the Division: Pharmaceutical Services / Essential Medicines List Committee Secretariat at the Ministry of Health and Social Services in Windhoek. Comments and requests will then be discussed at the next Essential Medicines List Committee (EMLC) meeting. These meetings will take place twice a year.

Proposals for changes to the Nemlist and/ or the STGs must be submitted using the appropriate form (Refer to annex 4 of this document). It is important that sufficient evidence is submitted (preferably controlled clinical trials) to support any request for change.

The form makes provision for: `

1. Request for changes to various sections of the STGs
2. Request for changes to the Nemlist; this includes:
 - Addition of a medicine to the Nemlist
 - Deletion of a medicine from the Nemlist
 - Replacement of one medicine on the Nemlist with another
 - Changing the level of availability of a Nemlist medicine

Please note that the requesting institution must fill in sections A of the form as well as *either* section B or section C. In instances where the changes proposed affect both the STGs and the Nemlist, both sections B and C should be completed.

Original forms in A4 format will be available from the Regional Pharmacists.

Completed forms may be submitted at any time.

2. Restricted Use Items

2.1. IMAI-R use items

These medicines will be available for use at health centres and clinics designated as IMAI sites and that have staff that have been trained in IMAI. They can also be stocked at District Hospital level and above, and used as normal AB class items in these facilities. Restrictions for medicines in this category are described in detail in Chapter 2.4 of this document.

The following guidelines shall apply for IMAI-R items:

1. These items will only be issued to patients at clinics and health centers implementing IMAI.

2. Treatment has to be initiated by a medical officer or an IMAI- trained nurse.
3. The clinic or health center implementing IMAI must keep a register of all patients on each IMAI-R medicine to document the receipt and issue of these medicines.
4. Hospital pharmacies will only issue the IMAI-R medicines against these registers.

If these medicines are to be taken on a chronic basis or over a long term, the patient has to be reviewed at least once every three months by a medical officer or an IMAI- trained nurse and a fresh prescription written out.

The following items are classified under the IMAI-R category:

012	Codeine Phosphate	30mg	Tablets
011	Chlorpromazine	25mg	Tablets
011	Chlorpromazine	100mg	Tablets
051	Dexamethasone	0.5mg	Tablets
063	Emulsifying Ointment		Ointment
011	Haloperidol	1.5mg	Tablets
011	Haloperidol	5mg	Tablets
051	Ibuprofen	200mg; 400mg	Tablets
051	Loperamide	2mg	Tablets
021	Metoclopramide	5mg/ml	(Injection (2ml
051	Metoclopramide	10mg	Tablets
062	Povidone - Iodine	10%	Solution
021	All 1 st line ARVs for adults		Tablets

2.2. Restricted (R) items

These are items that are only to be used in certain specific situations. All health workers must ensure that they familiarise themselves with the restrictions that apply to the use of these items. Restrictions for medicines in this category are described in detail in Chapter 2.4 of this document. Principal Medical Officers, Medical Superintendents and Pharmacy staff are responsible for ensuring that these medicines are ONLY used as stipulated here.

2.3. General Control Measures for All Restricted Use (R) Items

Restricted Use items should be kept in a locked cupboard in the pharmacy and the key kept by the Pharmacist/ Pharmacist's Assistant in charge of the pharmacy.

2.4. Specific Control Measures for Individual Restricted Use Items

The following table gives specific control measures that must be adhered to for individual Restricted Use items, in addition to the general measures mentioned above.

Medicine & Indications	Restrictions on prescribers & level of care
<p>1. Antineoplastics, Immunosuppressives and other oncology medicines</p> <p>To be used only under the direction of the Medical Oncologist or a Specialist in a relevant field</p> <ul style="list-style-type: none"> ○ Azathioprine 50mg Tablets ○ Bleomycin 15 000 Units Powder for Injection ○ Busulphan 2mg Tablets ○ Chlorambucil 5mg Tablets ○ Capecitabine 500mg tablets ○ Cisplatin 10mg; 50mg Powder for Injection ○ Cyclophosphamide 200mg; 500mg; 1g Powder for Injection ○ Cyclophosphamide 50mg Tablets ○ Cyclosporin 25mg; 100mg Capsules ○ Cyclosporin 100mg/ml Solution ○ Cytosine arabinoside 100mg Powder for Injection ○ Dacarbazine 100mg; 200mg Powder for Injection ○ Dactinomycin 0.5mg/ml Injection ○ Docetaxel 20mg; 80mg Injection ○ Doxorubicin 10mg; 50mg Powder for Injection ○ Doxorubicin 4-Epi 10mg; 50mg Powder for Injection ○ Etoposide 100mg Powder for Injection ○ Folinic acid 15mg tablets ○ Fluorouracil 250mg; 500mg Powder for Injection ○ Hydroxyurea 500mg Capsules ○ Ifosfamide 500mg Powder for Injection ○ L – Asparaginase 10 000 IU/ml Injection ○ Lefolinic Acid 12.5mg/ml Injection ○ Lenograstim 263mcg Powder for injection ○ Letrozole 2.5mg Tablets ○ Melphalan 2mg Tablets ○ Mercaptopurine 50mg Tablets ○ Mesna 100mg/ml Injection (4ml) ○ Methotrexate 2.5mg Tablets ○ Methotrexate 25mg/ml Injection (2ml) ○ Mitomycin (Streptomyces Caespitosis) 2mg Powder for Injection 	<p>Medical Oncologist or Specialist in a relevant field</p>
<p>2. Acyclovir (Aciclovir) 400mg/800mg tablets</p> <p>Treatment of patients presenting <u>within 72 hours</u> of the first symptoms of:</p> <ul style="list-style-type: none"> ✓ herpes zoster ✓ corneal ulcers associated with Herpes simplex infections ✓ chicken pox pneumonia ✓ chicken pox in immuno-compromised patients 	<p>Specialists and Medical x (MO) only</p>
<p>Syndromic management of Genital Ulcers and Genital Herpes infection in accordance to STI guidelines</p>	<p>Any competent prescribers</p>

Medicine & Indications	Restrictions on prescribers & level of care
<p>** IMPORTANT **</p> <p>Therapy with Acyclovir Tablets should be initiated at the earliest sign or symptoms of any of the above conditions.</p> <p>Acyclovir <i>should not</i> be used in patients presenting more than 72 hours after first signs or symptoms, as it has no proven efficacy in such cases.</p> <p>Acyclovir <i>should not</i> be used for the following diagnoses:</p> <ul style="list-style-type: none"> ✗ Cold sores (herpes simplex) ✗ Chicken pox in immuno-competent patients ✗ Cytomegalovirus (CMV) infections ✗ Infectious mononucleosis 	
<p>3. Bedaquiline 100mg Tablets</p>	
<p>Restricted for the management of X-DR and MDR TB</p>	<p>MO or Specialist</p>
<p>4. Benzoyl Peroxide 5% Gel/ Cream</p>	
<p>To be used according to the guidelines for the management of acne. Hospital and regional pharmacists are to closely monitor usage of this medicine and institute appropriate control measures if necessary</p>	<p>Dermatologist or MO District hospital (class C) or higher</p>
<p>5. Biperiden 5mg/ml Injection</p>	
<p>To be used only in patients exhibiting extra pyramidal symptoms induced by medicines. The medicine should not be used in place of oral biperidine used to prevent extra pyramidal symptoms. It should be reserved for admitted patients who present with drug induced extra-pyramidal symptoms. This will reduce the practice of initiating all patients empirically on anti-cholinergic oral therapy.</p>	<p>MO District hospital (class C) or higher</p>
<p>6. Captopril 12.5mg tablets</p>	
<p>To be used <u>only</u> for hypertension in paediatric patients</p> <p>Treatment must be initiated only by a designated specialist at the national referral hospital</p> <p>Formula for preparing Captopril 1mg/ml oral solution</p> <ul style="list-style-type: none"> - 2 x Captopril 12.5mg tablets + 25ml of Simple Syrup B.P. (<i>refer to Namibia Pharmaceutical SOPs for preparation of Simple Syrup B.P.</i>) - To be stored in a refrigerator; expires after 30 days; shake well before use 	<p>MO or Specialist District hospital (class C) or higher</p>
<p>7. Cefixime 200mg tablets</p>	

Medicine & Indications	Restrictions on prescribers & level of care
Approved indications: ✓ Urethral Discharge ✓ Vaginal Discharge ✓ Partner of mother of baby with <i>ophthalmia neonatorum</i> ✓ Mother of baby with <i>ophthalmia neonatorum</i>	Any competent prescriber
8. Ceftriaxone 250mg injection	
Approved indications: ✓ Pelvic Inflammatory Disease ✓ Alternative to Cefixime for the treatment of Urethral Discharge ✓ Alternative to Cefixime for the treatment of Vaginal Discharge ✓ Scrotal swelling ✓ Alternative to Cefixime for treatment of mother of baby with <i>ophthalmia neonatorum</i> ✓ Alternative to Cefixime for treatment of partner of the mother of baby with <i>ophthalmia neonatorum</i> ✓ Baby with <i>ophthalmia neonatorum</i>	Any competent prescriber
✓ Treatment of infections <i>only when</i> results of Culture and Sensitivity testing show that the organism is resistant to other available medicines	MO or specialist
9. Ciprofloxacin 500mg tablets	
Treatment of infections <i>only when</i> results of Culture and Sensitivity testing show that the organism is resistant to other available medicines	MO or specialist
10. Ciprofloxacin 2mg/ml IV Infusion	
Treatment of infections in in-patient with UTIs. This medicine should not be initiated in possible TB cases.	MO or specialist
11. Delamanid 50mg Tablets	
For the management of X-DR TB & M-DR. TB	MO or specialist
12. Enoxaparin 40mg/0.4ml injection	
Approved indications for which Enoxaparin is recommended rather than Heparin: Pre- and post-op prophylaxis of venous thrombo-embolism for the following conditions: <ul style="list-style-type: none"> ○ Elective total hip replacement (THR) ○ Elective total knee replacement (TKR) ○ Major trauma ○ Acute spinal cord injury 	MO or specialist Intermediate hospitals (Class B) and higher

Medicine & Indications	Restrictions on prescribers & level of care
13. Erythromycin 1% topical solution	
<p>For the topical treatment of acne; to forestall development of resistance by normal flora, the following guide should be used:</p> <ul style="list-style-type: none"> ○ Combination therapy with benzoyl peroxide is recommended. Alternatively, short intervening courses of benzoyl peroxide during antibacterial therapy may help to eliminate any resistant bacteria that have been selected. ○ The course of this topical antibacterial should not be continued for longer than necessary (<i>although treatment should be used for at least 6 months</i>) 	<p>MO or Specialist District hospital (class C) or higher</p>
14. Erythromycin 125mg/5ml oral suspension	
<p>Azithromycin is preferred to Erythromycin because it is better tolerated, has better tissue penetration and more favourable pharmacokinetics. It has a similar spectrum of activity to Erythromycin; though slightly lower <i>in vitro</i> activity of Azithromycin against gram positive organisms is not thought to be clinically significant</p> <p>Erythromycin should be used for the treatment of the following conditions for which safety and effectiveness of Azithromycin have not been established:</p> <ul style="list-style-type: none"> ○ paediatric patients less than 6 months of age with otitis media, acute bacterial sinusitis or community acquired pneumonia ○ paediatric patients under 2 years of age with pharyngitis/ tonsillitis 	<p>Any competent prescriber All levels of care</p>
15. Fluconazole 200mg tablets	
<p>To be used according to Diflucan Partnership agreement for cryptococcal meningitis and oesophageal candidiasis (thrush) in HIV infected patients</p>	<p>MO or specialist</p>
<p>Cryptococcal meningitis (CM)</p> <ul style="list-style-type: none"> ○ To be used for treatment of cryptococcal meningitis (at a dose of 400mg/day for 8-10 weeks) after initial treatment with Amphotericin B IV for 14 days. ○ Only to be used for initial treatment of cryptococcal meningitis when there is no amphotericin B available because fluconazole has been shown to be not as effective as amphotericin B infusion. ○ Continue fluconazole at 200mg/day as maintenance therapy for life ○ <i>Should not</i> be used for primary prophylaxis of cryptococcal meningitis 	
<p>Oesophageal Candidiasis (OC)</p> <ul style="list-style-type: none"> ○ Dose Adults: 200 mg orally once daily for 14 days 	



Medicine & Indications	Restrictions on prescribers & level of care
16. Linezolid 2mg/ml IV Infusion	
Restricted for use against Vancomycin resistant aorganisms and Drug resistant TB on advise of NTLP.	MO or Specialist
17. Linezolid 400mg and 600mg Tablets	
Restricted for the management of X-DR	MO or Specialist
18. Mefloquine 250mg tablets	
To be used for prophylaxis of malaria according to the Malaria guidelines	MO or Specialist District hospital (class C) or higher
19. Moxifloxacin 400mg Tablets	
Restricted for use by specialists for X-DR	MO or Specialist
20. Permethrin 5% Cream	
Approved indications: ○ 1 st line treatment for scabies in children (less than 12 years old) ○ 2 nd line treatment for scabies in all patients	MO or specialist District hospital (class C) or higher
21. Voriconazole 200mg/20ml Infusion	
To be used as an alternative to amphotericin B for patients with infections showing resistance to fluconazole	MO or specialist

3. The NEMLIST- Organised Along the Main Therapeutic Groups

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
A ALIMENTARY TRACT AND METABOLISM					
Stomatologicals, Mouth Preparations					
062	Chlorhexidine Mouth Wash †	0.20%	Liquid	ABC	N
062	Gentian Violet	0.50%	Solution	ABC	E
063	Nystatin	100,000 units/g	Topical Cream	AB	E
051	Nystatin	100,000 units	Uncoated Tablets	ABC	E
061	Nystatin	100,000 units/ml	Oral Suspension	ABC	E
063	Oral Anaesthetic Gel		Oral Gel	AB	N

† This item should be prepared at District Hospitals for supply to clinics.

Antacids, Antiflatulents					
061	Aluminium Hydroxide + Magnesium Hydroxide Suspension	300mg/5ml	Suspension	A	E
051	Aluminium Hydroxide/Magnesium Trisil.		Tablets	ABC	E

Anti-Peptic Ulcerants					
021	Esomeprazole IV	40mg/5ml	Powder for Injection	AB	E
051	Omeprazole	20mg	Capsules	AB	E
051	Ranitidine	150mg	Tablets	AB	E
021	Ranitidine	25mg/ml	Injection (2ml)	A	E
061	Sucralfate	1g/5ml	Suspension	S	E

Antispasmodics and Anticholinergics					
021	Glycopyrolate	0.2mg/ml	Injection (2ml)	AB	N
051	Hyoscine Butyl Bromide	10mg	Tablets	ABC	E
021	Hyoscine Butyl Bromide	20mg/ml	Injection	AB	E

Antiemetics and Antinauseants					
052	Cyclizine	50mg	Suppositories	AB	N
051	Metoclopramide	10mg	Tablets	IMAI-R	E
021	Metoclopramide	5mg/ml	Injection (2ml)	IMAI-R	E
021	Ondansetron	2mg/ml	Injection (4ml)	R	E
051	Ondansetron	8mg	Tablets	R	E
011	Prochlorperazine	12.5mg	Injection	S	E
062	Promethazine	5mg/5ml	Syrup	AB	E
011	Promethazine	25mg/ml	Injection	AB	V
051	Promethazine	10mg	Tablets	AB	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
Laxatives					
051	Bisacodyl	5mg	Tablets	ABC	E
052	Bisacodyl	10mg	Suppositories	AB	N
052	Glycerine Paediatric		Suppositories	ABC	N
061	Lactulose	3.3g/5ml	Liquid	S	N
061	Phosphate Comp.		Enema	AB	E
061	Sennosides A+B	142mg/71ml	Liquid	AB	E

Antidiarrhoeals, Intestinal Anti-Inflammatory and Anti-Infective Agents					
051	Loperamide	2mg	Tablets	IMAI-R	E
	Oral rehydration salts (WHO formula)		Powder	ABC	V
051	Sulphasalazine	500mg	Tablets	A	E

Digestives, including Enzymes					
051	Pancrelipase	234.2mg	Capsules	S	N

Insulins					
042	Insulin Zinc, Long Acting	100u/ml	Injection	A	V
042	Insulin, Isophane, Intermediate Acting	100u/ml	Injection	AB	V
042	Insulin, Soluble + Isophane (30/70)		Injection	AB	V
042	Insulin, Soluble, Short Acting	100u/ml	Injection	AB	V

Oral Antidiabetics					
051	Glibenclamide	5mg	Tablets	ABC#	E
051	Gliclazide	80mg	Tablets	AB	E
051	Metformin	500mg	Tablets	AB	E

These items are available at clinics and health centres for follow up treatment only

Vitamins					
051	Ascorbic Acid (Vitamin C)	100mg	Tablets	AB	N
051	Cholecalciferol, Ergocalciferol (Vitamin D)	5,000 IU	Tablets	A	E
051	Cholecalciferol, Ergocalciferol (Vitamin D)	5,000 IU/ml	Drops	A	N
021	Cyanocobalamine (Vitamin B12)	1,000 mcg/ml	Injection	AB	E
051	Multivitamin		Tablets	ABC	N
051	Multivitamin		Syrup	ABC	N
042	Multivitamin (Vitamin A, D, K), Adults		Infusion	A	E
042	Multivitamin (Vitamin A, D, K), Paediatr.		Infusion	A	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
042	Multivitamin		Injection	A	E
051	Nicotinamide	50mg	Tablets	AB	E
051	Pyridoxine Hydrochloride (Vitamin B6)	25mg	Tablets	ABC#	E
051	Retinol (Vitamin A)		Capsules	ABC	V
051	Thiamine (Vitamin B1)	100mg	Tablets	AB	E
021	Thiamine Hydrochloride (Vitamin B1)	100mg/ml	Injection	A	N

Mineral Supplements

021	Calcium Chloride	10%	Injection	AB	E
021	Calcium Gluconate	10%	Injection	AB	E
051	Calcium Gluconate	300mg	Tablets	AB	N
042	Electrolytes/Trace Elements, Adults		Injection	A	E
042	Electrolytes/Trace Elements, Paediatr.		Injection	A	E
021	Magnesium Sulphate	500mg/ml	Injection (2ml)	ABC	V
021	Potassium Chloride	15%	Injection	AB	V
051	Potassium Chloride	600mg	Slow Release Tabs	AB	E
021	Sodium Bicarbonate	4%	Injection	AB	V
021	Sodium Bicarbonate	8%	Injection	AB	V
021	Sodium Chloride	20%	Injection	A	E
051	Zinc (as sulphate)	10mg	Tablets	ABC	E
051	Zinc (as sulphate)	20mg	Tablets	ABC	E
061	Zinc (as sulphate)	10mg/5ml	Liquid	ABC	E

Total Parenteral Nutrition

042	Pre-filled 3-chamber TPN Bag with Electrolytes		Infusion (2/3L)	S	E
-----	--	--	-----------------	---	---

B BLOOD AND BLOOD FORMING ORGANS

	Anticoagulants				
051	Aspirin	300mg	Tablets	ABC#	E
051	Enoxaparin	40mg/0.4ml	Injection (ampoules)	R	E
042	Heparin	1000iu/ml	Injection	AB	V
042	Heparin	5000iu/ml	Injection	AB	V
051	Warfarin Sodium	5mg	Tablets	AB	V

Anti-Haemorrhagics

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
063	Bismuth Iodoform Paste		Paste	ABC	N
021	Phytomenadione	10mg/ml	Injection	AB	E
021	Phytomenadione	2mg/ml	Injection (0.5ml)	AB*	V
021	Protamine Sulphate	1%	Injection	AB	E
021	Tranexamic Acid	100mg/ml	Injection	AB	E
051	Tranexamic Acid	500mg	Tablets	S	N

* These items will also be available to clinics and health centres conducting deliveries

Anti - Anaemic Preparations					
051	Ferrous Fumarate + Folic Acid		Tablets	ABC	E
061	Ferrous Gluconate	250mg/5ml	Syrup	ABC	E
051	Ferrous Preparation	65mg (iron)	Tablets	ABC	E
051	Folic Acid	5mg	Tablets	AB	E
021	Cyanocobalamine (Vitamin B12)	1,000 mcg/ml	Injection	AB	E

Blood and Related Products					
021	Albumin, human	4%	Injectable Solution	S	E
021	Albumin, human	20%	Injectable Solution	S	E
031	Colloidal Plasma expander (HES130/0.4)	6%	Infusion	AB	V

IV Solutions					
031	Amino Acid Solution 5.5% with Electrolyt.	500ml	Infusion	A	E
031	Amino Acid Solution 8.5% with Electrolyt.	500ml	Infusion	A	E
031	Amino Acid Solution 8.5% w/o Electrolyt.	500ml	Infusion	A	E
031	Amino Acid Soln + Dextrose + Electrolyt.	500ml	Infusion	A	E
031	Darrows 1/2 strength with 5% Dextrose	200ml	Infusion	ABC	V
031	Dextrose 5% in 0.45% NaCl	1,000ml	Infusion	ABC	V
031	Dextrose 5% in 0.2% NaCl	200ml	Infusion	AB	V
031	Dextrose 5% in Water	200ml	Infusion	AB	V
031	Dextrose 5% in Water	1,000ml	Infusion	AB	V
031	Dextrose 5% in Water	50ml	Infusion	A	E
031	Dextrose 50% 500ml in 1000ml bag	1,000 ml	Infusion	A	V
042	Fat Emulsion 10%	500ml	Infusion	A	E
042	Fat Emulsion 20%	500ml	Infusion	A	E
031	Maintenance Soln. + 10% Dextrose	1,000 ml	Infusion	AB	E
031	Maintenance Soln. + 5% Dextrose	1,000 ml	Infusion	A	E
031	Maintenance Sol., Neonatal	200ml	Infusion	AB	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
031	Maintenance Sol., Neon., Potassium-Free	200ml	Infusion	A	E
031	Maintenance Sol., Paediatric, + 5% Dextr.	200ml	Infusion	A	E
031	Plasmolyte B	1,000 ml	Infusion	ABC	V
031	Plasmolyte B	200ml	Infusion	AB	E
031	Ringers Lactate	1,000 ml	Infusion	ABC	V
031	Sodium Bicarbonate 4.2%	500ml	Infusion	A	E
031	Sodium Chloride 0.45%	1,000 ml	Infusion	AB	E
031	Sodium Chloride 0.9%	1,000 ml	Infusion	ABC	V
031	Sodium Chloride 0.9%	200ml	Infusion	AB	E
031	Sodium Chloride 0.9%	50ml	Infusion	A	N
031	Sodium Chloride 5%	200ml	Infusion	AB	E
031	Mannitol 20%	200ml	Infusion	AB	E
031	Mannitol for Irrigation 5%	3,000 ml	Solution	AB	N
031	Sodium Chloride 0.9% in Pour Bottles	1,000 ml	Solution	AB	N
031	Sodium Chloride 0.9%	3,000ml	Solution	S	N

Peritoneal Dialysis Solutions

031	Peritoneal Dialysis Solution + Dextrose 2%; 1L in 2L Spike		Solution	AB	V
031	Peritoneal Dialysis Solution + Dextrose 2%; 2L in 3L Luer		Solution	A	
031	Perit. Dialysis Soln+Dextrose 4.25%; 1L in 2L Spike		Solution	AB	V
031	Perit. Dialysis Soln+Dextrose 4.25%; 2L in 3L Luer		Solution	A	
031	Haemodialysis Bath	5,000 ml	Solution	A	V
031	Haemodialysis Bath for Chronic Cases		Solution	S	E

Water

021	Water for Injection	5ml	Injection	ABC	V
021	Water for Injection	10ml	Injection	ABC	V
031	Water for Irrigation in Bags	1,000 ml	Solution	AB	N
031	Water for Irrigation in Pour Bottle	1,000 ml	Solution	ABC	N
031	Sterile Water for Irrigation	3,000ml	Solution	S	N

Enzymes

042	Hyaluronidase	300 IU/ml	Injection (5ml)	A	N
-----	---------------	-----------	-----------------	---	---

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
C CARDIOVASCULAR SYSTEM					
Cardiac Therapy					
021	Bretilium Tosylate	50mg/ml	Injection (10ml)	S	V
051	Digoxin	0.25mg	Tablets	AB	E
061	Digoxin	0.05mg/ml	Liquid	AB	E
021	Digoxin	0.25mg/ml	Injection (2ml)	AB	N
021	Lignocaine	2%	Injection (i.v.)	AB	V
051	Mexiletine	50mg	Tablets	S	E
051	Clopidrogel	75mg	Tablets	S	E

Cardiac Stimulants					
021	Dopamine	40mg/ml	Injection (5ml)	A	V
021	Dobutamine	12.5mg/ml	Injectable Sol (20ml)	A	E
021	Ephedrine Hydrochloride	3mg/ml	Injection	AB	E

Vasodilators Used in Cardiac Disease					
051	Glyceryl Trinitrate	0.5mg	Tablets (sublingual)	AB	V
051	Isosorbide Dinitrate	10mg	Tablets	AB	E
051	Isosorbide Dinitrate	40mg	Tablets	AB	E

Other Cardiac Preparations					
021	Atropine Sulphate	0.5mg/ml	Injection	AB	V
021	Glycopyrolate	0.2mg/ml	Injection (2ml)	AB	N

Lipid Lowering Agents					
051	Simvastatin	20mg	Tablets	S	E
051	Simvastatin	40mg	Tablets	S	E

Hypotensives					
021	Adenosine	3mg/ml	Injection	A	E
021	Amiodarone	50mg/ml	Injection	A	E
051	Amlodipine	5mg	Tablets	S	N
051	Dihydralazine	25mg/ml	Injection	AB	V
051	Diltiazem	90mg	Tablets	S	N
051	Doxazosin	1mg	Tablets	AB	E
051	Doxazosin	2mg	Tablets	AB	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
051	Doxazosin	4mg	Tablets	AB	E
051	Flecainide	100mg	Tablets	S	E
051	Methyldopa	250mg	Tablets	AB	V
051	Minoxidil	5mg	Tablets	S	N
051	Minoxidil	10mg	Tablets	S	N
051	Nifedipine	5mg	Capsules	S	E
051	Valsartan	80mg	Tablets	A	E
051	Verapamil	40mg	Tablets	AB	E
051	Verapamil	80mg	Tablets	AB	E
021	Verapamil	2.5mg/ml	Injection (2ml)	AB	N

Agents Acting on Renin-Angiotensin System

051	Captopril	12.5mg	Tablets	R	E
051	Perindopril (or Alternative)	4 mg	Tablets	ABC#	E

Diuretics

051	Amiloride + Hydrochlorothiazide	5mg + 50mg	Tablets	ABC#	V
051	Furosemide	40mg	Tablets	ABC#	E
021	Furosemide	10mg/ml	Injection (2ml)	AB	V
021	Furosemide	10mg/ml	Injectable Sol (25ml)	AB	N
046	Furosemide	10mg/ml	Liquid	AB	N
051	Hydralazine	25mg	Tablets	AB	E
051	Indapamide	2.5mg	Tablets	AB	N
051	Spirolactone	25mg	Tablets	AB	E

Beta Blocking Agents

051	Atenolol	50mg	Tablets	ABC#	E
051	Carvedilol	25mg	Tablets	AB	E
051	Propranolol	10mg	Tablets	AB	E
051	Propranolol	40mg	Tablets	AB	E
021	Propranolol	1mg/ml	Injection	AB	E

D DERMATOLOGICALS

Topical Antifungals

063	Benzoic Acid Comp.Ointment		Ointment	ABC	N
063	Clotrimazole	1%	Cream	AB	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
051	Griseofulvin	125mg	Tablets	AB	E
063	Nystatin Topical	100,000 IU/g	Cream	AB	E
063	Terbinafine	1%	Cream	S	N

Topical Anti-Haemorrhoids

052	Bismuth Subgallate Compound		Suppositories	ABC	N
-----	-----------------------------	--	---------------	-----	---

Soft Paraffin and Fat Products

063	Aqueous Cream		Cream	AB	N
063	Emulsifying Ointment		Ointment	IMAI-R	N
063	Zinc Cream		Cream	ABC	N

Antipruritics

062	Calamine		Lotion	ABC	N
-----	----------	--	--------	-----	---

Coal Tar, Sulfur and Resorcin Products

063	Coal Tar		Ointment	AB	N
063	Ichthammol		Ointment	ABC	N
001	Salicylic Acid		Powder	AB	N

Antibiotics and Chemotherapeutics (Dermatologicals)

063	Chlortetracycline	30mg/g	Ointment	ABC	N
063	Gentamicin	0.10%	Cream	S	N
062	Podophyllin	15%	Paint	AB	E
063	Silversulfadiazine	1%	Ointment	AB	E

Corticosteroids, plain

063	Betamethasone Valerate	0.10%	Cream	AB	E
063	Clobetasol Propionate	0.05%	Cream	S	E
063	Clobetasol Propionate	0.05%	Ointment	S	E
063	Fluticasone	0.05%	Cream	S	N
063	Fluticasone	0.05%	Ointment	S	N
063	Hydrocortisone	1%	Ointment	AB	E

Corticosteroids, combinations

063	Betamethasone + Gentamicin	0.05% + 0.1%	Ointment	S	N
-----	----------------------------	--------------	----------	---	---

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
063	Calcipotriol + Betamethasone Dipropionate	50mcg +05mg/g	Ointment	S	N

Antiseptics and Disinfectants

062	Alcohol (Ethanol) (Spirit Vini. Rect.)	96%	Solution	AB	E
062	Acriflavine		Emulsion	AB	N
062	Chlorhexidine	4%	Scrub	AB	N
062	Chlorhexidine	5%	Solution	AB	E
062	Chlorhexidine	20%	Solution	AB	E
062	Glutaraldehyde		Solution	AB	E
062	Glycerin		Liquid	AB	N
062	Hydrogen Peroxide	6%	Solution	AB	N
062	Mercurochrome	1%	Solution	ABC	N
063	Povidone - Iodine	10%	Ointment	ABC	E
062	Povidone - Iodine	10%	Solution	IMAI-R	E
062	Povidone - Iodine	7.5%	Scrub	ABC	N
001	Silver Nitrate		Pencil	AB	N
062	Sodium Hypochlorite (stabilised, sterilising fluid)		Solution	ABC	E
062	Spirits, Methylated		Solution	ABC	E

Anti-Acne Preparations

051	Acitretin	25mg	Tablets	S	N
063	Benzoyl Peroxide	5%	Cream/ gel	R	N
051	Cyproterone Acetate + Ethinylestradiol	2mg + 35mcg	Tablets	S	N
062	Erythromycin	1%	Topical solution	R	N
051	Isotretinoin	20mg	Capsules	S	N
063	Tretinoin	0.05%	Cream	S	N

Others

063	Lubricating Jelly		Ointment	ABC	N
063	Methyl Salicylate		Ointment	ABC	N

E GENITO-URINARY SYSTEM & SEX HORMONES

Gynaecological Anti-Infectives, Antiseptics & Alkalyising Agents

063	Chlorhexidine Obstetric	1%	Cream	AB [*]	E
052	Clotrimazole	500mg	Vaginal Tablets	ABC	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
061	Potassium Citrate		Solution	ABC	N
052	Povidone - Iodine	200mg	Pessaries	S	N
065	Salbutamol	500mcg/ml	Injection	AB	V

Oxytocics

042	Dinoprost F2 alpha	5mg/ml	Injection	S	N
042	Ergometrine Maleate	0.5mg/ml	Injection	AB ^x	V
042	Ergometrine Maleate + Oxytocin	0.5mg + 5IU/ml	Injection	AB ^x	V
045	Gemeprost (or Prostaglandin E 2)	1mg (0.5mg)	Pessaries (Tablets)	S	E
051	Misoprostol	200mcg	Tablets	ABC-R	E
047	Prostaglandin E2	1mg/3g	Gel	S	E

Topical Contraceptives

114	Condoms (Latex Male)			ABC	V
114	Condoms (Female)			ABC	V
173	Intrauterine Contraceptive Device	260mg Cu		AB	E

Various Other Gynecologicals

021	Hexoprenaline	2.5mcg/ml	Injection (10ml)	AB ^x	E
Hormonal Contraceptives, systemic					
051	Levonorgestrel + Ethinylestradiol	150mcg + 30mcg	Tablets	ABC	E
051	Levonorgestrel + Ethinylestradiol	triphasic	Tablets	ABC	N
021	Medroxyprogesterone Acetate	150mg	Injection	ABC	E
051	Norethisterone	0.35mg	Tablets	ABC	E
021	Norethisterone Enanthate	200mg/ml	Injection	ABC	E
051	Norgesterel + Ethinylestradiol	500mcg + 50mcg	Tablets	ABC	N

Estrogens

051	Conjugated Estrogens	0.625mg	Tablets	AB	E
063	Conjugated Estrogens	0.625mg/g	Cream	AB	N

Progestogens

051	Medroxyprogesterone	5mg	Tablets	AB	E
-----	---------------------	-----	---------	----	---

F SYSTEMIC HORMONES, excl. SEX HORMONES

Pituitary and Hypothalamic Hormones

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
051	Desmopressin	200mcg	Tablets	A	E
042	Ornipressin	5 IU/ml	Injection	S	E
042	Oxytocin	5 IU/ml	Injection	AB*	V
042	Oxytocin	10 IU/ml	Injection	AB	E

Systemic Corticosteroids

021	Betamethasone Disodium Phos + Acetate	3mg + 3mg/ml	Injection	S	N
051	Dexamethasone	0.5mg	Tablets	IMAI-R	E
021	Dexamethasone Sodium Phosphate	5mg/ml	Injection	AB	V
021	Hydrocortisone Sodium Succinate	100mg	Powder for Injection	ABC	V
021	Methylprednisolone Sodium Succinate	1 g	Powder for Injection	AB	N
051	Prednisone	5mg	Tablets	AB	V
051	Prednisone	50mg	Tablets	S	E

Thyroid Preparations

051	Levothyroxine Sodium	50mcg	Tablets	AB	E
051	Levothyroxine Sodium	100mcg	Tablets	AB	E

Antithyroid Preparations

051	Carbimazole	5mg	Tablets	AB	E
-----	-------------	-----	---------	----	---

Iodine Therapy

051	Iodine	10%	Aq. Solution	AB	N
-----	--------	-----	--------------	----	---

G GENERAL ANTI - INFECTIVES. SYSTEMIC

Cephalosporins

021	Cefazolin	1 gram	Powder for Injection	AB	E
061	Cefixime	200mg	Tablets	R	V
051	Cefradine	500mg	Capsules	AB	E
061	Cefradine	125mg/5ml	Suspension	A	E
021	Ceftriaxone	250mg	Powder for Injection	R	V
021	Ceftriaxone	1g	Powder for Injection	A	E
021	Cefuroxime	750mg	Powder for Injection	AB	E
051	Cefuroxime	250mg	Tablets	AB	E
061	Cefuroxime	125mg/5ml	Suspension	AB	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
Penicillins					
061	Amoxicillin	125mg/5ml	Syrup	ABC	V
051	Amoxicillin	250mg	Capsules	ABC	V
061	Amoxicillin + Clavulanic Acid	125mg/31mg	Suspension	AB	E
	Amoxicillin + Clavulanic Acid	1000/200 mg	Injection	AB	V
051	Amoxicillin + Clavulanic Acid	875/125mg	Tablets	AB	E
021	Ampicillin	250mg	Powder for Injection	AB	V
021	Ampicillin	500mg	Powder for Injection	AB	V
021	Benzathine Benzylpenicillin	2.4 million IU	Powder for Injection	ABC	V
021	Benzyl-, + Benzathine + Procaine Penicillin	1.2 million IU	Powder for Injection	ABC	N
021	Benzylpenicillin	1 million IU	Powder for Injection	AB	E
051	Cloxacillin	250mg	Capsules	AB	E
061	Cloxacillin	125mg/5ml	Syrup	AB	E
021	Cloxacillin	250mg	Powder for Injection	AB	E
021	Cloxacillin	500mg	Powder for Injection	AB	E
051	Phenoxymethylpenicillin	250mg	Tablets	ABC	V
061	Phenoxymethylpenicillin	250mg/5ml	Syrup	ABC	V
021	Piperacillin + Tazobactam	4g + 500mg	Powder for Injection	S	E
021	Procaine Benzyl Penicillin	3g (3 million IU) or 300mg/ml	Powder for Injection (10ml)	ABC	V

All other Antibiotics					
021	Amikacin	250mg/ml	Injection (2ml)	A	V
051	Azithromycin	1g	Tablets	ABC	V
061	Azithromycin	200mg/5ml	Suspension	ABC	V
051	Chloramphenicol	250mg	Capsules	AB	E
061	Chloramphenicol	125mg/5ml	Suspension	AB	E
021	Chloramphenicol	1g	Powder for Injection	AB	E
051	Ciprofloxacin	500mg	Tablets	R	V
021	Ciprofloxacin	2mg/ml	Infusion (200ml)	R	V
051	Clindamycin	150mg	Capsules	A	E
021	Clindamycin	150mg/ml	Injection (4ml)	S	E
051	Doxycycline	100mg	Capsules	ABC	V
061	Erythromycin	125mg/5ml	Suspension	R	E
051	Erythromycin	250mg	Tablets	ABC	V
021	Erythromycin	1g	Powder for Injection	A	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
051	Fusidic Acid	250mg	Capsules	AB	N
061	Fusidic Acid	250mg/5ml	Syrup	S	N
021	Fusidic Acid	500mg	Powder for Injection	S	E
021	Gentamicin	10mg/ml	Injection (2ml)	AB	V
021	Gentamicin	40mg/ml	Injection (2ml)	AB	V
051	Hydroxychloroquine	200mg	Tablets	AB	E
021	Linezolid	2mg/ml	Infusion (300ml)	R	V
051	Linezolid	400mg	Tablets	R	V
051	Linezolid	600mg	Tablets	R	V
021	Meropenem	500mg	Injection	S	V
021	Meropenem	1g	Injection	S	V
051	Nalidixic Acid	500mg	Tablets	ABC	V
061	Nalidixic Acid	250mg/5ml	Suspension	ABC	V
051	Nitrofurantoin	100mg	Capsules	AB	E
021	Streptomycin	1g	Powder for Injection	ABC#	V
021	Vancomycin	500mg	Injection	S	V
021	Vancomycin	1g	Injection	S	V

Systemic Antimycotics excluding Griseofulvin

041	Amphotericin B	50mg	Powder for Injection	AB	V
021	Fluconazole	2mg/ml	Solution for Infusion	R	N
051	Fluconazole	200mg	Tablets	R	E
051	Itraconazole	100mg	Capsules	AB	E
051	Ketoconazole	200mg	Tablets	A	E
021	Voriconazole	200mg/ml	Injection	R	E

Sulphonamides with Anti-Infectives in Combination

051	Co-trimoxazole	80mg/400mg	Tablets	ABC	E
061	Co-trimoxazole	40mg/200mg/5ml	Suspension	ABC	E
021	Co-trimoxazole	80mg/400mg/5ml	Injection	AB	E
051	Metronidazole	400mg	Tablets	ABC	V
061	Metronidazole	200mg/5ml	Syrup	ABC	E
052	Metronidazole	1g	Suppositories	AB	E
021	Metronidazole	5mg/ml	Injection (100ml)	S	V

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
Tuberculostatics, excluding Streptomycin					
051	Beaquiline	100mg	Tablets	R	V
021	Capreomycin	1g	Injection	S	V
021	Cefoxitin	100mg	Injection	S	V
051	Clarithromycin	500mg	Tablets	S	V
051	Cycloserine	250mg	Tablets	AB	V
051	Delamanid	50mg	Tablets	R	V
051	Ethambutol	100mg	Tablets	ABC#	V
051	Ethambutol	400mg	Tablets	ABC#	V
051	Ethionamide	250mg	Tablets	AB	V
051	Isoniazid	100mg	Tablets	ABC#	V
021	Kanamycin	1g	Injection	AB	V
051	Levofloxacin	250mg	Tablets	AB	V
051	Moxifloxacin	400mg	Tablets	R	V
021	Moxifloxacin	400mg/250ml	Infusion	S	V
001	p-Amino Salicylic Acid	4g	Sachet	S	V
051	Pyrazinamide	500mg	Tablets	ABC#	V
051	Rifampicin	150mg	Capsules	ABC#	V
051	Rifampicin	450mg	Tablets	ABC#	V
061	Rifampicin	100mg/5ml	Syrup	ABC#	V
061	Rifampicin + Isoniazid	60mg +30mg	Tablets	ABC#	V
061	Rifampicin + Isoniazid	150mg +75mg	Tablets	ABC	V
061	Rifampicin + Isoniazid + Pyrazinamide	60mg +30mg +150mg	Tablets	ABC#	V
061	Rifampicin + Isoniazid + Ethambutol	150mg + 75mg + 275mg	Tablets	ABC#	V
061	Rifampicin + Isoniazid + Pyrazinamide + Ethambutol	150mg + 75mg + 400mg + 275mg	Tablets	ABC	V

Leprostatics					
051	Clofazimine	100mg	Tablets	A	V
051	Dapsone	100mg	Tablets	A	V
051	Rifampicin	450 mg	Tablets	ABC#	V

Antivirals for Systemic Use					
051	Acyclovir (Aciclovir)	400mg	Tablets	R	E
051	Acyclovir (Aciclovir)	800mg	Tablets	R	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
Antiretrovirals					
012	Abacavir	300mg	Tablets	AB	V
012	Abacavir	20mg/ml	Liquid	AB	V
012	Abacavir	60mg	Tablets	AB	V
012	Didanosine	025mg	Capsules/Tablets	AB	V
012	Didanosine	050mg	Capsules/Tablets	AB	V
012	Didanosine	100mg	Capsules/Tablets	AB	V
012	Didanosine	200mg	Capsules/Tablets	AB	V
012	Didanosine	250mg	Capsules/Tablets	AB	V
012	Didanosine	400mg	Capsules/Tablets	AB	V
012	Efavirenz	050mg	Capsules/Tablets	AB	V
012	Efavirenz	100mg	Capsules/Tablets	AB	V
012	Efavirenz	200mg	Capsules/Tablets	AB	V
012	Efavirenz	600mg	Tablets	IMAI-R	V
012	Efavirenz	30mg/ml	Syrup	AB	V
012	Indinavir	400mg	Capsules	AB	V
012	Lamivudine	50mg/5ml	Oral Solution	AB	V
012	Lamivudine	150mg	Tablets	IMAI-R	V
012	Lamivudine + Abacavir	30mg + 60mg	Tablets	AB	V
012	Lamivudine + Stavudine	030mg + 06mg	Tablets	AB	V
012	Lamivudine + Stavudine	060mg + 12mg	Tablets	AB	V
012	Lamivudine + Stavudine	150mg + 30mg	Tablets	IMAI-R	V
012	Lamivudine + Stavudine + Abacavir	150mg + 300mg + 300mg	Tablets	IMAI-R	V
012	Lamivudine + Stavudine + Nevirapine	030mg + 06mg + 050mg	Tablets	AB	V
012	Lamivudine + Stavudine + Nevirapine	060mg + 12mg + 100mg	Tablets	AB	V
012	Lamivudine + Stavudine + Nevirapine	150mg + 30mg + 200mg	Tablets	IMAI-R	V
012	Lamivudine + Tenofovir	300mg + 300mg	Tablets	IMAI-R	V
012	Lamivudine + Zidovudine	30mg + 60mg	Tablets	AB	V
012	Lamivudine + Zidovudine	150mg + 300mg	Tablets	IMAI-R	V
012	Lamivudine + Zidovudine + Nevirapine	150mg + 300mg + 200mg	Tablets	IMAI-R	V
012	Lamivudine + Zidovudine + Nevirapine	30mg + 60mg + 50mg	Tablets	AB	V

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
012	Lopinavir + Ritonavir	(400 + 100) mg/5ml	Oral Solution	AB	V
012	Lopinavir + Ritonavir	200mg + 50mg	Tablets	AB	V
012	Lopinavir + Ritonavir	100mg + 25mg	Tablets	AB	V
012	Nevirapine	200mg	Tablets	IMAI-R	V
012	Nevirapine	50mg/5ml	Suspension	AB	V
012	Ritonavir	100mg	Capsules	AB	V
012	Stavudine	15mg	Capsules	AB	V
012	Stavudine	20mg	Capsules	AB	V
012	Stavudine	30mg	Capsules	AB	V
012	Stavudine	1mg/ml	Liquid	AB	V
012	Tenofovir	300mg	Tablets	IMAI-R	V
012	Tenofovir + Emtricitabine	300mg+200mg	Tablets	IMAI-R	V
012	Tenofovir + Emtricitabine + Efavirenz	300mg+200mg+600mg	Tablets	IMAI-R	V
012	Zidovudine	50mg/5ml	Syrup	AB	V
012	Zidovudine	100mg	Tablets	AB	V
012	Zidovudine	300mg	Tablets	IMAI-R	V

Immune Sera and Immunoglobulins

044	Anti-D (RH) Immunoglobulin	200mg	Injection	AB	V
044	Diphtheria Antitoxin	20,000 IU	Injection	S	V
044	Hepatitis B Immunoglobulin		Injection	AB	V
044	Human Antibody Globulin		Injection	A	E
044	Rabies Immunoglobulin		Injection	AB	V
044	Measles Immunoglobulin		Injection	AB	V
044	Scorpion Antiserum		Injection	AB	V
044	Snake Venom Antiserum Polyvalent		Injection	ABC	V
044	Spider Venom Antiserum		Injection	AB	V
044	Tetanus Immunoglobulin	500 IU/ml	Injection	AB	V
044	Tetanus Immunoglobulin	250 IU/ml	Injection	AB	V
044	Varicella Zoster Immunoglobulin		Injection	S	E

Vaccines

043	B.C.G.		Injection	ABC	V
043	Diphtheria + Tetanus (D.T.)		Injection	ABC	V
043	Diphtheria + Pertussis + Tetanus (D.P.T.)		Injection	ABC	V

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
043	Hepatitis B		Injection	AB	V
043	Measles Vaccine		Injection	ABC	V
043	Meningococcal Vaccine A & C		Injection	AB	V
043	Poliomyelitis (oral, with dropper)		Oral Vaccine	ABC	V
043	Rabies Vaccine (Cell culture Vaccine)		Injection	ABC#	V
043	Tetanus Toxoid (adsorbed)		Injection	ABC	V
041	Tuberculin as MANTOUX (diagnostic)		Injection	AB	E
043	Typhoid		Injection	A	V
043	Yellow Fever		Injection	A	V

H ANTINEOPLASTIC AND IMMUNOSUPPRESSIVES

Cytostatic Agents

042	Bleomycin	15,000 Units	Powder for Injection	R	E
051	Busulphan	2mg	Tablets	R	E
051	Capecitabine	500mg	Tablets	R	E
051	Chlorambucil	5mg	Tablets	R	E
042	Cisplatin	10mg	Powder for Injection	R	E
042	Cisplatin	50mg	Powder for Injection	R	E
021	Cyclophosphamide	200mg	Powder for Injection	R	E
021	Cyclophosphamide	500mg	Powder for Injection	R	E
021	Cyclophosphamide	1g	Powder for Injection	R	E
051	Cyclophosphamide	50mg	Tablets	R	E
042	Cytosine arabinoside	100mg	Powder for Injection	R	E
042	Dacarbazine	100mg	Powder for Injection	R	E
042	Dacarbazine	200mg	Powder for Injection	R	E
042	Dactinomycin	0.5mg/ml	Injection	R	E
042	Docetaxel	20mg	Injection	R	E
042	Docetaxel	80mg	Injection	R	E
042	Doxorubicin	10mg	Powder for Injection	R	E
042	Doxorubicin	50mg	Powder for Injection	R	E
042	Doxorubicin 4-Epi	10mg	Powder for Injection	R	E
042	Doxorubicin 4-Epi	50mg	Powder for Injection	R	E
021	Etoposide	100mg	Powder for Injection	R	E
021	Fluorouracil	250mg	Powder for Injection	R	E
021	Fluorouracil	500mg	Powder for Injection	R	E
051	Hydroxyurea	500mg	Capsules	R	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
021	Ifosfamide	500mg	Powder for Injection	R	E
021	L - Asparaginase	10,000 IU/ml	Injection	R	E
021	Lenograstim	263mg	Injection	R	E
051	Melphalan	2mg	Tablets	R	E
051	Mercaptopurine	50mg	Tablets	R	E
051	Methotrexate	2.5mg	Tablets	R	E
021	Methotrexate	25mg/ml	Injection (2ml)	R	E
042	Mitomycin (Streptomyces Caespitosis)	2mg	Powder for Injection	R	E
042	Mitoxanthrone	2mg/ml	Injection	R	E
051	Procarbazine	50mg	Tablets	R	E
042	Rituximab	100mg/10ml	Concentrate for solution for infusion	S	E
051	Thioguanine	40mg	Tablets	R	E
042	Trastuzumab	440mg	Powder for Injection	S	E
042	Vinblastine	10mg	Powder for Injection	R	E
042	Vincristine	1mg	Powder for Injection	R	E

Detoxifying Agents

051	Folinic acid	15mg	Tablets	R	E
021	Lefolnic Acid	12.5mg	Injection	R	E
021	Mesna	100mg/ml	Injection (4ml)	R	E

Endocrine Therapy

051	Letrozole	2.5mg	Tablets	R	E
051	Tamoxifen	20mg	Tablets	R	E

Immunosuppressives

051	Azathioprine	50mg	Tablets	R	E
051	Cyclosporin	25mg	Capsules	R	E
051	Cyclosporin	100mg	Capsules	R	E
061	Cyclosporin	100mg/ml	Solution	R	E

Radiation Protection

063	Mexenone		Cream	ABC	N
-----	----------	--	-------	-----	---

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
I MUSCULOSKELETAL SYSTEM					
Anti-Inflammatory/Anti-Rheumatic Products, Non-Steroids					
051	Aspirin	300mg	Tablets	ABC#	E
051	Celecoxib	100mg	Capsules	AB	E
051	Celecoxib	200mg	Capsules	AB	E
021	Diclophenac	25mg/ml	Injection (3ml)	AB*	E
051	Ibuprofen	200mg	Tablets	IMAI-R	E
051	Ibuprofen	400mg	Tablets	IMAI-R	E
051	Indomethacin	25mg	Capsules	AB	E
052	Indomethacin	100mg	Suppositories	A	N
051	Penicillamine, d-	125mg	Tablets	S	E

Muscle Relaxants					
042	Atracurium Besilate	10mg/ml	Injection	AB	V
051	Baclofen	10mg	Tablets	S	N
051	Baclofen	25mg	Tablets	S	N
042	Pancuronium Bromide	2mg/ml	Injection (2ml)	A	E
042	Rocuronium	50mg/5mL	Injection (5ml)	A	E
042	Suxamethonium Chloride	50mg/ml	Injection (2ml)	AB	E

Anti-Gout Preparations					
051	Allopurinol	300mg	Tablets	AB	E
051	Colchicine	0.5mg	Tablets	AB	N
051	Probenecid	500mg	Tablets	AB	E

J CENTRAL NERVOUS SYSTEM					
Inhalation Anaesthetics					
011	Enflurane		Liquid	AB	E
011	Halothane		Liquid	AB	V
011	Isoflurane		Liquid	S	E
	Nitrous Oxide		Gas	AB	V
	Oxygen		Gas	ABC	V
011	Sevoflurane		Liquid	A	N

Intravenous/Intramuscular Anaesthetics					
012	Alfentanyl	0.5mg/ml	Injection	S	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
011	Etomidate	2mg/ml	Injection	A	N
012	Fentanyl	0.05mg/ml	Injection	AB	E
011	Ketamine	10mg/ml	Injection	AB	V
011	Ketamine	50mg/ml	Injection	AB	V
011	Propofol	10mg/ml	Injection	AB	E

Local Anaesthetics, excluding Dermatologicals

021	Bupivacaine	0.50%	Injection	AB	V
062	Ethyl Chloride		Spray	AB	N
063	Lignocaine	2%	Jelly	AB	N
062	Lignocaine	100mg/g (10%)	Spray	AB	N
021	Lignocaine	1%	Injection	ABC	V
021	Lignocaine	2%	Dental Cartridge	AB	E
021	Lignocaine + Epinephrine	2%	Dental Cartridge	AB	E
021	Lignocaine Spinal (to be mixed with 7.5% Glucose)	5%	Injection	AB	N

Analgesics

051	Aspirin	300mg	Tablets	ABC#	E
012	Codeine Phosphate	30mg	Tablets	IMAI-R	E
012	Methadone	2mg/5ml	Syrup	AB	E
012	Morphine Sulphate	10mg/ml	Injection	AB	V
012	Morphine Sulphate	15mg/ml	Injection	AB	V
012	Morphine Sulphate		Powder	AB	E
012	Morphine Sulphate	10mg	Slow Release Tablets	AB	E
012	Morphine Sulphate	30mg	Slow Release Tablets	AB	E
051	Paracetamol	500mg	Tablets	ABC	E
061	Paracetamol	120mg/5ml	Syrup	ABC	E
021	Paracetamol	500mg/50ml	Infusion	AB	V
021	Paracetamol	1g/100ml	Infusion	AB	V
051	Paracetamol + Codeine Phosphate	500mg + 8mg	Tablets	AB	N
012	Pethidine Hydrochloride		Injection	AB	E
012	Tilidine	50mg/0.5ml	Drops	AB	N
011	Tramadol Hydrochloride	50mg	Tablets	AB	N
011	Tramadol Hydrochloride	50mg/ml	Injection (2ml)	AB	N

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
Anti-Migraine Preparations					
051	Ergotamine + Caffeine + Cyclizine	2mg + 100mg + 50mg	Tablets	AB	N
051	Flunarizine	5mg	Tablets	S	N

Anti-Epileptics					
051	Carbamazepine	200mg	Tablets	ABC#	V
061	Carbamazepine	100mg/5ml	Suspension	AB	E
011	Diazepam	2mg	Tablets	AB	E
011	Diazepam	5mg	Tablets	AB	E
011	Diazepam	5mg/ml	Injection (2ml)	ABC	V
011	Diazepam	5mg	Suppositories	AB	N
011	Phenobarbitone	15mg	Tablets	ABC#	E
011	Phenobarbitone	30mg	Tablets	ABC#	E
011	Phenobarbitone	15mg/5ml	Syrup	ABC#	E
011	Phenobarbitone	200mg/ml	Injection	AB	E
051	Phenytoin	100mg	Tablets	ABC#	V
061	Phenytoin	125mg/5ml	Suspension	AB	E
021	Phenytoin	250mg/5ml	Injection	AB	E
051	Valproate, Sodium	200mg	Tablets	AB	N
061	Valproic Acid	200mg/5ml	Solution	AB	N
061	Valproate, Sodium + Valproic acid CR	333mg + 145mg	Tablets	AB	N

Anti-Parkinson Agents					
051	Biperiden	2mg	Tablets	AB	E
051	Biperiden	5mg/ml	Injection	R	V
051	Bromocriptine	2.5mg	Tablets	S	N
051	Carbidopa + Levodopa	25mg + 100mg	Tablets	AB	E
011	Trihexyphenidyl (Benzhexol)	2mg	Tablets	S	N
011	Trihexyphenidyl (Benzhexol)	5mg	Tablets	S	N

Antipsychotics					
011	Chlorpromazine	25mg/ml	Injection (2ml)	ABC	E
011	Chlorpromazine	25mg	Tablets	IMAI-R	E
011	Chlorpromazine	100mg	Tablets	IMAI-R	E
011	Clozapine	25mg	Tablets	S	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
011	Clozapine	100mg	Tablets	S	E
011	Droperidol	5mg/ml	Injection	A	N
011	Flupenthixol	20mg/ml	Injection	AB	E
011	Fluphenazine Decanoate	25mg/ml	Injection	AB	V
011	Fluphenazine Hydrochloride	2.5mg/ml	Injection	AB	N
011	Haloperidol	1.5mg	Tablets	IMAI-R	E
011	Haloperidol	5mg	Tablets	IMAI-R	N
011	Haloperidol	1mg/ml	Injection (5ml)	AB	E
011	Hydroxyzine	25mg	Tablets	AB	E
011	Hydroxyzine	50mg/ml	Injection (2ml)	AB	E
011	Lithium Carbonate	25mg	Tablets	S	E
011	Olanzapine	10mg	Tablets	S	E
011	Pimozide	1mg	Tablets	S	N
011	Prochlorperazine	12.5mg/ml	Injection	AB	E
011	Risperidone	1mg	Tablets	S	E
011	Risperidone	2mg	Tablets	S	E
011	Sulpiride	50mg	Tablets	AB	E
011	Thioridazine	25mg	Tablets	S	E
011	Thioridazine	100mg	Tablets	S	E
011	Zuclopenthixol acetate	50mg/ml	Injection	A	E

Anxiolytics

011	Diazepam	2mg	Tablets	AB	E
011	Diazepam	5mg	Tablets	AB	E
011	Diazepam	5mg/ml	Injection (2ml)	ABC	V
011	Lorazepam	1mg	Tablets	A	N
011	Midazolam	5mg/ml	Injection (3ml)	S	E

Antidepressants

011	Amitriptyline	25mg	Tablets	AB	E
011	Fluoxetine	20mg	Tablets	A	E
011	Imipramine	10mg	Tablets	AB	E
011	Trimipramine	25mg	Tablets	A	E

Psychostimulants

012	Methylphenidate	10mg	Tablets	S	N
-----	-----------------	------	---------	---	---

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
Other Nervous System Drugs					
021	Neostigmine	2.5mg/ml	Injection	AB	V
051	Pyridostigmine	60mg	Tablets	S	N

K ANTIPARASITIC PRODUCTS					
Antiprotozoals					
051	Metronidazole	400mg	Tablets	ABC	V
061	Metronidazole	200mg/5ml	Suspension	ABC	V
052	Metronidazole	1g	Suppositories	AB	E
021	Metronidazole	5mg/ml	Injection (100ml)	S	V

Antimalarials					
051	Artemether + Lumefantrine	20mg + 120mg	Tablets	ABC	V
051	Mefloquine	250mg	Tablets	R	N
051	Proguanil	100mg	Tablets	ABC	E
051	Pyrimethamine + Sulphadoxine	25mg + 500mg	Tablets	ABC	E
021	Quinine Dihydrochloride	300mg/ml	Injection	AB	V
051	Quinine Sulphate	300mg	Tablets	AB	V

Anthelmintics					
061	Albendazole	100mg/5ml	Suspension	ABC	E
051	Albendazole	200mg	Tablets	ABC	E
051	Praziquantel	600mg	Tablets	AB	V

Ectoparasiticides, including Scabicides					
062	Benzyl Benzoate		Emulsion	ABC	E
063	Permethrin	5%	Cream	R	N

L RESPIRATORY SYSTEM					
Nasal Decongestants, Topical Preparations					
065	Beclomethasone Dipropionate (or other corticosteroid)	050mcg/dose	Aqueous Nasal spray	AB	N
064	Oxymetazoline	0.05%	Drops	S	N

Anti-Asthmatics					
065	Beclomethasone Dipropionate MDI	50mcg/dose	Inhaler	AB	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
065	Beclomethasone Dipropionate MDI	200mcg/dose	Inhaler	AB	E
021	Adrenalin (Epinephrine)	1mg/ml (1:1000)	Injection	ABC	V
021	Hexoprenaline	2.5mcg/ml	Injection (10ml)	AB	E
065	Ipratropium Bromide Nebuliser Solution	0.25mg/ml	Nebuliser Solution	S	N
051	Salbutamol	2mg	Tablets	AB	V
061	Salbutamol	2mg/5ml	Syrup	AB	E
065	Salbutamol MDI or powder for inhalation	100mcg/dose	Inhaler	ABC	E
065	Salbutamol solution for inhalation	5mg/ml (0.5%)	Nebuliser Solution	ABC	V
065	Sodium Chromoglycate MDI or Powder for Inhalation	5mg/dose	Inhaler	S	N
051	Theophylline Anhydrous	200mg	Slow Release Tabs	ABC#	E
061	Theophylline Oral Solution (alcohol free)	5mg/ml	Solution	ABC#	E

Mucolytic

061	N-Acetylcysteine	200mg/sachet	Sachet/Powder	S	N
-----	------------------	--------------	---------------	---	---

Systemic Antihistamines

011	Alimemazine (Trimeprazine)	30mg/5ml	Syrup	AB	N
051	Cetirizine	10mg	Tablets	AB	E
061	Chlorphenamine	2mg/5ml	Syrup	ABC	E
051	Chlorphenamine	4mg	Tablets	ABC	E
051	Oxatomide	30mg	Tablets	S	N
061	Promethazine	5mg/5ml	Syrup	AB	E
011	Promethazine	25mg/ml	Injection	AB	V
051	Promethazine	10mg	Tablets	AB	E

Surfactant

	Total Phospholipids	25mg/ml	Suspension	AB	E
--	---------------------	---------	------------	----	---

M SENSORY ORGANS

OPHTHALMOLOGICALS

Anti-Infectives

064	Chloramphenicol	0.5%	Eye Drops	A	E
064	Chloramphenicol	1%	Eye Ointment	ABC	V
064	Chloramphenicol	1%	S/Dose Eye Oint.	AB	N
064	Fusidic acid	10mg/g	Eye Ointment	AB	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
064	Gentamicin	0,3%	Eye Drops	R	E
064	Ofloxacin	0.3%	Eye Drops	R	E
064	Tetracycline *	1%	Eye Ointment	AB	E

* N.B. if chloramphenicol eye ointment is not available then issue this to clinics instead

Antifungal Agents					
064	Natamycin	5%	Eye Drops	S	N

Corticosteroids					
064	Dexamethasone	0.1%	Eye Drops	AB	E
064	Fluorometholone	0.1%	Eye Drops	AB	N
064	Prednisolone	10%	Eye Drops	R	E

Corticosteroids and Anti-Infectives in Combination					
064	Betamethasone + Neomycin	0.1% + 0.5%	Eye Ointment	AB	N
064	Dexamethasone + Chloramphenicol	0.1% + 0.5%	Eye Ointment	AB	N
064	Dexamethasone + Neomycin + Polymyxin B	0.1% + 3,500 U/ ml + 6,000 U/ml	Eye Drops	R	N

Glaucoma Preparations					
051	Acetazolamide	250mg	Tablets	AB	E
064	Acetylcholine + Mannitol	40mg	Eye Drops	A	E
064	Brimonidine	0.20%	Eye Drops	S	N
064	Levobunolol (or Alternative Beta Blocker)	0.50%	Eye Drops	AB	E
064	Pilocarpine	2%	Eye Drops	AB	E
064	Bimatoprost + Timolol	0.03% + 0.5%	Eye Drops	AB	E

Mydriatics and Cycloplegics					
064	Atropine	1%	Eye Drops	AB	E
064	Cyclopentolate	2%	Eye Drops	R	E
064	Cyclopentolate + Phenylephrine	(2mg + 10mg)/ ml	Eye Drops	AB	E
064	Phenylephrine	3%	Eye Drops	A	E
064	Chondroitin Sulphate + Sodium Hyaluronate Ophthalmic Viscosurgical Device	40mg+30mg/ml	Injection (0.5ml)	S	E

Various Other Agents					
064	Ketorolac	0.50%	Eye Drops	A	N

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
064	Oxymetazoline	Paed. 0.025%	Eye Drops	ABC	N
064	Sodium Cromoglycate	2%	Eye Drops	R	N
064	Sodium Cromoglycate	4%	Eye Ointment	S	N
042	Sodium Hyaluronate	10mg	Injection	S	N
	Anaesthetic				
064	Oxybuprocaine	0.40%	Eye Drops	AB	E

Diagnostic Agents

003	Fluorescein Sodium		Strips	AB	E
-----	--------------------	--	--------	----	---

Tear Replacements

064	Balanced Ophthalmic Irrigation		Solution	A	N
064	Dextran 70 + Hydroxypropylmethylcellulose		Eye Drops	AB	N
064	Liquid Lanolin	30mg/g	Eye Ointment	AB	N

OTOLOGICALS

Anti-Infectives

064	Acetic Acid in Spirits †	1%	Ear Drops	ABC	E
064	Wax Softening Solution (* NOT for take home)		Ear Drops	ABC	N

† This item should be prepared at District Hospitals for supply to clinics.

N VARIOUS

Anti-Poisoning Agents

001	Activated Charcoal		Powder	AB	E
021	Desferrioxamine	500mg	Powder for Injection	A	E
021	Dimercaprol	50mg/ml	Injection (2ml)	A	E
021	Methylene Blue	1%	Injection	AB	E
021	N-Acetylcysteine	200mg/ml	Injection	AB	E
021	Naloxone	0.02mg/ml	Injection	AB	V
021	Naloxone	0.4mg/ml	Injection	AB	V
021	Protamine Sulphate	10mg/ml	Injection	AB	E
001	Sodium Polystyrene Sulfonate		Resin	S	N

Diagnostic Agents

003	Blood Glucose Test Strip (20-800mg/dl)		Strips	ABC	E
003	Litmus Paper, Blue		Strips	AB	N

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
003	Pap Smear Fixative			ABC	E
041	Pregnancy Diagnostic Kit (HCG)			ABC	N
003	Urine Test Strip (Glucose, Prot, pH, Ket., Blood)		Strips	ABC	E
003	Urine Test Strip (Glucs, Prot., pH, Ket., Blood,Nitr., Bili., Urobil.)		Strips	AB	E

Nutritional Products					
061	Balanced Enteral Nutrition for Children 2-10 Years		Solution	S	E
061	Balanced Liquid Feed with Fiber - isotonic		Solution	S	N
061	Balanced, Partially Hydrolysed Liquid Feed, low residue		Solution	S	E
002	Calorie Supplement Powder with Dextrose Polymer		Powder	S	N
002	Casein Predominant Starter Formula		Powder	AB	E
021	Dextrose	50%	Injection (20ml)	AB	V
002	Dextrose Monohydrate		Powder	AB	N
061	Diabetic Special Adult Tube Feed e.g. Diben		Solution (500ml)	S	E
002	Lactose-free Milk Supplement		Powder	AB	E
061	Lipid Concentrate (med. chain & essential fatty acids)		Solution	S	N
002	Milk Protein Food Supplement		Powder	S	E
002	Nutrient Denser Follow up Formula		Powder	AB	E
002	Nutritional Supplement		Powder	AB	V
061	Polymeric Adult Feeds (ready to hang)e.g. Fresubin Original		Solution (1000ml)	S	V
061	Polymeric Paediatric Feeds (ready to hang) e.g. Nutren Junior ready to drink	Suitable for children 1-10 year old	Solution	S	V
002	Premature Feeding Formula		Powder	AB	V
061	Premature Infant Formula (ready to drink) e.g. Pre-NAN		Solution	S	V
002	Realimentration Powder for Infant Diarrh.		Powder	S	V
061	Semi Elemental Adult Feeds (ready to hang) e.g. Peptamen Neutral Dual		Solution (500ml)	S	V
061	Semi Elemental Paediatric Feeds (ready to hang) e.g. Peptamen Junior AdvanceNeutral Dual	NB: Suitable for children 1-10 year old	Solution (500ml)	S	V
002	Soya Protein Milk Substitute		Powder	A	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
061	Special Immune Modulating Adult Feeds (ready to hang) e.g. Impact entral neutral dual		Solution	S	E
061	Specialized Pharmaco- nutrients e.g. Intes-tamin		Solution	S	E
002	Whey Predominant Starter Formula		Powder	AB	N
001	Therapeutic complex of Minerals and Vitamins			AB	E
001	Ready to use Therapeutic Food (RUTF) Plumpy Nut	92g, 500kcal	Sachet	AB*	E
001	Ready to use Supplementary Therapeutic Food	92g, 500kcal	Sachet	AB*	E

Other Non-Therapeutic Products

062	ECG Gel		Gel	AB	
001	Soda Lime with Indicator		Powder	AB	
062	Ultrasound Gel		Gel	AB	

4. The Nemlist – Alphabetical Index

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
012	Abacavir	20mg/ml	Liquid	AB	V
012	Abacavir	300mg	Tablets	AB	V
012	Abacavir	60mg	Tablets	AB	V
051	Acetazolamide	250mg	Tablets	AB	E
064	Acetic Acid in Spirits †	1%	Ear Drops	ABC	E
064	Acetylcholine + Mannitol	40mg	Eye Drops	A	E
051	Acitretin	25mg	Tablets	S	N
062	Acriflavine		Emulsion	AB	N
001	Activated Charcoal		Powder	AB	E
051	Acyclovir (Aciclovir)	400mg	Tablets	R	E
051	Acyclovir (Aciclovir)	800mg	Tablets	R	E
021	Adenosine	3mg/ml	Injection	A	E
021	Adrenalin (Epinephrine)	1mg/ml (1:1000)	Injection	ABC	V
061	Albendazole	100mg/5ml	Suspension	ABC	E
051	Albendazole	200mg	Tablets	ABC	E
021	Albumin, human	4%	Injectable Solution	S	E
021	Albumin, human	20%	Injectable Solution	S	E
062	Alcohol (Ethanol) (Spirit Vini. Rect.)	96%	Solution	AB	E
012	Alfentanyl	0.5mg/ml	Injection	S	E
011	Alimemazine (Trimeprazine)	30mg/5ml	Syrup	AB	N
051	Allopurinol	300mg	Tablets	AB	E
061	Aluminium Hydroxide + Magnesium Hydroxide Suspension	300mg/5ml	Suspension	A	E
051	Aluminium Hydroxide/Magnesium Trisil.		Tablets	ABC	E
021	Amikacin	250mg/ml	Injection (2ml)	A	V
051	Amiloride + Hydrochlorothiazide	5mg + 50mg	Tablets	ABC#	V
031	Amino Acid Soln + Dextrose + Electrolyt.	500ml	Infusion	A	E
031	Amino Acid Solution 5.5% with Electrolyt.	500ml	Infusion	A	E
031	Amino Acid Solution 8.5% w/o Electrolyt.	500ml	Infusion	A	E
031	Amino Acid Solution 8.5% with Electrolyt.	500ml	Infusion	A	E
021	Amiodarone	50mg/ml	Injection	A	E
011	Amitriptyline	25mg	Tablets	AB	E
051	Amlodipine	5mg	Tablets	S	N
051	Amoxicillin	250mg	Capsules	ABC	V
061	Amoxicillin	125mg/5ml	Syrup	ABC	V
	Amoxicillin + Clavulanic Acid	1000/200 mg	Injection	AB	V
061	Amoxicillin + Clavulanic Acid	125mg/31mg	Suspension	AB	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
051	Amoxicillin + Clavulanic Acid	875/125mg	Tablets	AB	E
041	Amphotericin B	50mg	Powder for Injection	AB	V
021	Ampicillin	250mg	Powder for Injection	AB	V
021	Ampicillin	500mg	Powder for Injection	AB	V
044	Anti-D (RH) Immunoglobulin	200mg	Injection	AB	V
063	Aqueous Cream		Cream	AB	N
051	Artemether + Lumefantrine	20mg + 120mg	Tablets	ABC	V
051	Ascorbic Acid (Vitamin C)	100mg	Tablets	AB	N
051	Aspirin	300mg	Tablets	ABC#	E
051	Aspirin	300mg	Tablets	ABC#	E
051	Aspirin	300mg	Tablets	ABC#	E
051	Atenolol	50mg	Tablets	ABC#	E
042	Atracurium Besilate	10mg/ml	Injection	AB	V
064	Atropine	1%	Eye Drops	AB	E
021	Atropine Sulphate	0.5mg/ml	Injection	AB	V
051	Azathioprine	50mg	Tablets	R	E
061	Azithromycin	200mg/5ml	Suspension	ABC	V
051	Azithromycin	1g	Tablets	ABC	V
043	B.C.G.		Injection	ABC	V
051	Baclofen	10mg	Tablets	S	N
051	Baclofen	25mg	Tablets	S	N
061	Balanced Enteral Nutrition for Children 2-10 Years		Solution	S	E
061	Balanced Liquid Feed with Fiber - isotonic		Solution	S	N
064	Balanced Ophthalmic Irrigation		Solution	A	N
061	Balanced, Partially Hydrolysed Liquid Feed, low residue		Solution	S	E
051	Beaquiline	100mg	Tablets	R	V
065	Beclomethasone Dipropionate (or other corticosteroid)	050mcg/dose	Aqueous Nasal spray	AB	N
065	Beclomethasone Dipropionate MDI	200mcg/dose	Inhaler	AB	E
065	Beclomethasone Dipropionate MDI	50mcg/dose	Inhaler	AB	E
021	Benzathine Benzylpenicillin	2.4 million IU	Powder for Injection	ABC	V
063	Benzoic Acid Comp.Ointment		Ointment	ABC	N
063	Benzoyl Peroxide	5%	Cream/ gel	R	N
062	Benzyl Benzoate		Emulsion	ABC	E
021	Benzyl-, + Benzathine + Procaine Penicillin	1.2 million IU	Powder for Injection	ABC	N
021	Benzylpenicillin	1 million IU	Powder for Injection	AB	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
063	Betamethasone + Gentamicin	0.05% + 0.1%	Ointment	S	N
064	Betamethasone + Neomycin	0.1% + 0.5%	Eye Ointment	AB	N
021	Betamethasone Disodium Phos + Acetate	3mg + 3mg/ml	Injection	S	N
063	Betamethasone Valerate	0.10%	Cream	AB	E
064	Bimatoprost + Timolol	0.03% + 0.5%	Eye Drops	AB	E
051	Biperiden	5mg/ml	Injection	R	V
051	Biperiden	2mg	Tablets	AB	E
052	Bisacodyl	10mg	Suppositories	AB	N
051	Bisacodyl	5mg	Tablets	ABC	E
063	Bismuth Iodoform Paste		Paste	ABC	N
052	Bismuth Subgallate Compound		Suppositories	ABC	N
042	Bleomycin	15,000 Units	Powder for Injection	R	E
003	Blood Glucose Test Strip (20-800mg/dl)		Strips	ABC	E
021	Bretilium Tosylate	50mg/ml	Injection (10ml)	S	V
064	Brimonidine	0.20%	Eye Drops	S	N
051	Bromocriptine	2.5mg	Tablets	S	N
021	Bupivacaine	0.50%	Injection	AB	V
051	Busulphan	2mg	Tablets	R	E
062	Calamine		Lotion	ABC	N
063	Calcipotriol + Betamethasone Dipropionate	50mcg +05mg/g	Ointment	S	N
021	Calcium Chloride	10%	Injection	AB	E
021	Calcium Gluconate	10%	Injection	AB	E
051	Calcium Gluconate	300mg	Tablets	AB	N
002	Calorie Supplement Powder with Dextrose Polymer		Powder	S	N
051	Capecitabine	500mg	Tablets	R	E
021	Capreomycin	1g	Injection	S	V
051	Captopril	12.5mg	Tablets	R	E
061	Carbamazepine	100mg/5ml	Suspension	AB	E
051	Carbamazepine	200mg	Tablets	ABC#	V
051	Carbidopa + Levodopa	25mg + 100mg	Tablets	AB	E
051	Carbimazole	5mg	Tablets	AB	E
051	Carvedilol	25mg	Tablets	AB	E
002	Casein Predominant Starter Formula		Powder	AB	E
021	Cefazolin	1 gram	Powder for Injection	AB	E
061	Cefixime	200mg	Tablets	R	V
021	Cefoxitin	100mg	Injection	S	V
051	Cefradine	500mg	Capsules	AB	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
061	Cefradine	125mg/5ml	Suspension	A	E
021	Ceftriaxone	1g	Powder for Injection	A	E
021	Ceftriaxone	250mg	Powder for Injection	R	V
021	Cefuroxime	750mg	Powder for Injection	AB	E
061	Cefuroxime	125mg/5ml	Suspension	AB	E
051	Cefuroxime	250mg	Tablets	AB	E
051	Celecoxib	100mg	Capsules	AB	E
051	Celecoxib	200mg	Capsules	AB	E
051	Cetirizine	10mg	Tablets	AB	E
051	Chlorambucil	5mg	Tablets	R	E
051	Chloramphenicol	250mg	Capsules	AB	E
064	Chloramphenicol	0.5%	Eye Drops	A	E
064	Chloramphenicol	1%	Eye Ointment	ABC	V
021	Chloramphenicol	1g	Powder for Injection	AB	E
064	Chloramphenicol	1%	S/Dose Eye Oint.	AB	N
061	Chloramphenicol	125mg/5ml	Suspension	AB	E
062	Chlorhexidine	4%	Scrub	AB	N
062	Chlorhexidine	5%	Solution	AB	E
062	Chlorhexidine	20%	Solution	AB	E
062	Chlorhexidine Mouth Wash †	0.20%	Liquid	ABC	N
063	Chlorhexidine Obstetric	1%	Cream	AB*	E
061	Chlorphenamine	2mg/5ml	Syrup	ABC	E
051	Chlorphenamine	4mg	Tablets	ABC	E
011	Chlorpromazine	25mg/ml	Injection (2ml)	ABC	E
011	Chlorpromazine	100mg	Tablets	IMAI-R	E
011	Chlorpromazine	25mg	Tablets	IMAI-R	E
063	Chlortetracycline	30mg/g	Ointment	ABC	N
051	Cholecalciferol, Ergocalciferol (Vitamin D)	5,000 IU/ml	Drops	A	N
051	Cholecalciferol, Ergocalciferol (Vitamin D)	5,000 IU	Tablets	A	E
064	Chondroitin Sulphate + Sodium Hyaluronate Ophthalmic Viscosurgical Device	40mg+30mg/ml	Injection (0.5ml)	S	E
021	Ciprofloxacin	2mg/ml	Infusion (200ml)	R	V
051	Ciprofloxacin	500mg	Tablets	R	V
042	Cisplatin	10mg	Powder for Injection	R	E
042	Cisplatin	50mg	Powder for Injection	R	E
051	Clarithromycin	500mg	Tablets	S	V
051	Clindamycin	150mg	Capsules	A	E
021	Clindamycin	150mg/ml	Injection (4ml)	S	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
063	Clobetasol Propionate	0.05%	Cream	S	E
063	Clobetasol Propionate	0.05%	Ointment	S	E
051	Clofazimine	100mg	Tablets	A	V
051	Clopidogrel	75mg	Tablets	S	E
063	Clotrimazole	1%	Cream	AB	E
052	Clotrimazole	500mg	Vaginal Tablets	ABC	E
051	Cloxacillin	250mg	Capsules	AB	E
021	Cloxacillin	250mg	Powder for Injection	AB	E
021	Cloxacillin	500mg	Powder for Injection	AB	E
061	Cloxacillin	125mg/5ml	Syrup	AB	E
011	Clozapine	100mg	Tablets	S	E
011	Clozapine	25mg	Tablets	S	E
063	Coal Tar		Ointment	AB	N
012	Codeine Phosphate	30mg	Tablets	IMAI-R	E
051	Colchicine	0.5mg	Tablets	AB	N
031	Colloidal Plasma expander (HES130/0.4)	6%	Infusion	AB	V
114	Condoms (Female)			ABC	V
114	Condoms (Latex Male)			ABC	V
063	Conjugated Estrogens	0.625mg/g	Cream	AB	N
051	Conjugated Estrogens	0.625mg	Tablets	AB	E
021	Co-trimoxazole	80mg/400mg/5ml	Injection	AB	E
061	Co-trimoxazole	40mg/200mg/5ml	Suspension	ABC	E
051	Co-trimoxazole	80mg/400mg	Tablets	ABC	E
021	Cyanocobalamine (Vitamin B12)	1,000 mcg/ml	Injection	AB	E
021	Cyanocobalamine (Vitamin B12)	1,000 mcg/ml	Injection	AB	E
052	Cyclizine	50mg	Suppositories	AB	N
064	Cyclopentolate	2%	Eye Drops	R	E
064	Cyclopentolate + Phenylephrine	(2mg + 10mg)/ml	Eye Drops	AB	E
021	Cyclophosphamide	1g	Powder for Injection	R	E
021	Cyclophosphamide	200mg	Powder for Injection	R	E
021	Cyclophosphamide	500mg	Powder for Injection	R	E
051	Cyclophosphamide	50mg	Tablets	R	E
051	Cycloserine	250mg	Tablets	AB	V
051	Cyclosporin	100mg	Capsules	R	E
051	Cyclosporin	25mg	Capsules	R	E
061	Cyclosporin	100mg/ml	Solution	R	E
051	Cyproterone Acetate + Ethinylestradiol	2mg + 35mcg	Tablets	S	N

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
042	Cytosine arabinoside	100mg	Powder for Injection	R	E
042	Dacarbazine	100mg	Powder for Injection	R	E
042	Dacarbazine	200mg	Powder for Injection	R	E
042	Dactinomycin	0.5mg/ml	Injection	R	E
051	Dapsone	100mg	Tablets	A	V
031	Darrows 1/2 strength with 5% Dextrose	200ml	Infusion	ABC	V
051	Delamanid	50mg	Tablets	R	V
021	Desferrioxamine	500mg	Powder for Injection	A	E
051	Desmopressin	200mcg	Tablets	A	E
064	Dexamethasone	0.1%	Eye Drops	AB	E
051	Dexamethasone	0.5mg	Tablets	IMAI-R	E
064	Dexamethasone + Chloramphenicol	0.1% + 0.5%	Eye Ointment	AB	N
064	Dexamethasone + Neomycin + Polymyxin B	0.1% + 3,500 U/ ml + 6,000 U/ml	Eye Drops	R	N
021	Dexamethasone Sodium Phosphate	5mg/ml	Injection	AB	V
064	Dextran 70 + Hydroxypropylmethylcellulose		Eye Drops	AB	N
021	Dextrose	50%	Injection (20ml)	AB	V
031	Dextrose 5% in 0.2% NaCl	200ml	Infusion	AB	V
031	Dextrose 5% in 0.45% NaCl	1,000ml	Infusion	ABC	V
031	Dextrose 5% in Water	1,000ml	Infusion	AB	V
031	Dextrose 5% in Water	200ml	Infusion	AB	V
031	Dextrose 5% in Water	50ml	Infusion	A	E
031	Dextrose 50% 500ml in 1000ml bag	1,000 ml	Infusion	A	V
002	Dextrose Monohydrate		Powder	AB	N
061	Diabetic Special Adult Tube Feed e.g. Diben		Solution (500ml)	S	E
011	Diazepam	5mg/ml	Injection (2ml)	ABC	V
011	Diazepam	5mg/ml	Injection (2ml)	ABC	V
011	Diazepam	5mg	Suppositories	AB	N
011	Diazepam	2mg	Tablets	AB	E
011	Diazepam	2mg	Tablets	AB	E
011	Diazepam	5mg	Tablets	AB	E
011	Diazepam	5mg	Tablets	AB	E
021	Diclophenac	25mg/ml	Injection (3ml)	AB*	E
012	Didanosine	025mg	Capsules/Tablets	AB	V
012	Didanosine	050mg	Capsules/Tablets	AB	V
012	Didanosine	100mg	Capsules/Tablets	AB	V
012	Didanosine	200mg	Capsules/Tablets	AB	V
012	Didanosine	250mg	Capsules/Tablets	AB	V

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
012	Didanosine	400mg	Capsules/Tablets	AB	V
021	Digoxin	0.25mg/ml	Injection (2ml)	AB	N
061	Digoxin	0.05mg/ml	Liquid	AB	E
051	Digoxin	0.25mg	Tablets	AB	E
051	Dihydralazine	25mg/ml	Injection	AB	V
051	Diltiazem	90mg	Tablets	S	N
021	Dimercaprol	50mg/ml	Injection (2ml)	A	E
042	Dinoprost F2 alpha	5mg/ml	Injection	S	N
043	Diphtheria + Pertussis + Tetanus (D.P.T.)		Injection	ABC	V
043	Diphtheria + Tetanus (D.T.)		Injection	ABC	V
044	Diphtheria Antitoxin	20,000 IU	Injection	S	V
021	Dobutamine	12.5mg/ml	Injectable Sol (20ml)	A	E
042	Docetaxel	20mg	Injection	R	E
042	Docetaxel	80mg	Injection	R	E
021	Dopamine	40mg/ml	Injection (5ml)	A	V
051	Doxazosin	1mg	Tablets	AB	E
051	Doxazosin	2mg	Tablets	AB	E
051	Doxazosin	4mg	Tablets	AB	E
042	Doxorubicin	10mg	Powder for Injection	R	E
042	Doxorubicin	50mg	Powder for Injection	R	E
042	Doxorubicin 4-Epi	10mg	Powder for Injection	R	E
042	Doxorubicin 4-Epi	50mg	Powder for Injection	R	E
051	Doxycycline	100mg	Capsules	ABC	V
011	Droperidol	5mg/ml	Injection	A	N
062	ECG Gel		Gel	AB	
012	Efavirenz	050mg	Capsules/Tablets	AB	V
012	Efavirenz	100mg	Capsules/Tablets	AB	V
012	Efavirenz	200mg	Capsules/Tablets	AB	V
012	Efavirenz	30mg/ml	Syrup	AB	V
012	Efavirenz	600mg	Tablets	IMAI-R	V
042	Electrolytes/Trace Elements, Adults		Injection	A	E
042	Electrolytes/Trace Elements, Paediatr.		Injection	A	E
063	Emulsifying Ointment		Ointment	IMAI-R	N
011	Enflurane		Liquid	AB	E
051	Enoxaparin	40mg/0.4ml	Injection (ampoules)	R	E
021	Ephedrine Hydrochloride	3mg/ml	Injection	AB	E
042	Ergometrine Maleate	0.5mg/ml	Injection	AB*	V

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
042	Ergometrine Maleate + Oxytocin	0.5mg + 5IU/ml	Injection	AB*	V
051	Ergotamine + Caffeine + Cyclizine	2mg + 100mg + 50mg	Tablets	AB	N
021	Erythromycin	1g	Powder for Injection	A	E
061	Erythromycin	125mg/5ml	Suspension	R	E
051	Erythromycin	250mg	Tablets	ABC	V
062	Erythromycin	1%	Topical solution	R	N
021	Esomeprazole IV	40mg/5ml	Powder for Injection	AB	E
051	Ethambutol	100mg	Tablets	ABC#	V
051	Ethambutol	400mg	Tablets	ABC#	V
051	Ethionamide	250mg	Tablets	AB	V
062	Ethyl Chloride		Spray	AB	N
011	Etomidate	2mg/ml	Injection	A	N
021	Etoposide	100mg	Powder for Injection	R	E
042	Fat Emulsion 10%	500ml	Infusion	A	E
042	Fat Emulsion 20%	500ml	Infusion	A	E
012	Fentanyl	0.05mg/ml	Injection	AB	E
051	Ferrous Fumarate + Folic Acid		Tablets	ABC	E
061	Ferrous Gluconate	250mg/5ml	Syrup	ABC	E
051	Ferrous Preparation	65mg (iron)	Tablets	ABC	E
051	Flecainide	100mg	Tablets	S	E
021	Fluconazole	2mg/ml	Solution for Infusion	R	N
051	Fluconazole	200mg	Tablets	R	E
051	Flunarizine	5mg	Tablets	S	N
003	Fluorescein Sodium		Strips	AB	E
064	Fluorometholone	0.1%	Eye Drops	AB	N
021	Fluorouracil	250mg	Powder for Injection	R	E
021	Fluorouracil	500mg	Powder for Injection	R	E
011	Fluoxetine	20mg	Tablets	A	E
011	Flupenthixol	20mg/ml	Injection	AB	E
011	Fluphenazine Decanoate	25mg/ml	Injection	AB	V
011	Fluphenazine Hydrochloride	2.5mg/ml	Injection	AB	N
063	Fluticasone	0.05%	Cream	S	N
063	Fluticasone	0.05%	Ointment	S	N
051	Folic Acid	5mg	Tablets	AB	E
051	Folinic acid	15mg	Tablets	R	E
021	Furosemide	10mg/ml	Injectable Sol (25ml)	AB	N

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
021	Furosemide	10mg/ml	Injection (2ml)	AB	V
046	Furosemide	10mg/ml	Liquid	AB	N
051	Furosemide	40mg	Tablets	ABC#	E
051	Fusidic Acid	250mg	Capsules	AB	N
021	Fusidic Acid	500mg	Powder for Injection	S	E
061	Fusidic Acid	250mg/5ml	Syrup	S	N
064	Fusidic acid	10mg/g	Eye Ointment	AB	E
045	Gemeprost (or Prostaglandin E 2)	1mg (0.5mg)	Pessaries (Tablets)	S	E
063	Gentamicin	0.10%	Cream	S	N
064	Gentamicin	0.3%	Eye Drops	R	E
021	Gentamicin	10mg/ml	Injection (2ml)	AB	V
021	Gentamicin	40mg/ml	Injection (2ml)	AB	V
062	Gentian Violet	0.50%	Solution	ABC	E
051	Glibenclamide	5mg	Tablets	ABC#	E
051	Gliclazide	80mg	Tablets	AB	E
062	Glutaraldehyde		Solution	AB	E
062	Glycerin		Liquid	AB	N
052	Glycerine Paediatric		Suppositories	ABC	N
051	Glyceryl Trinitrate	0.5mg	Tablets (sublingual)	AB	V
021	Glycopyrolate	0.2mg/ml	Injection (2ml)	AB	N
021	Glycopyrolate	0.2mg/ml	Injection (2ml)	AB	N
051	Griseofulvin	125mg	Tablets	AB	E
031	Haemodialysis Bath	5,000 ml	Solution	A	V
031	Haemodialysis Bath for Chronic Cases		Solution	S	E
011	Haloperidol	1mg/ml	Injection (5ml)	AB	E
011	Haloperidol	1.5mg	Tablets	IMAI-R	E
011	Haloperidol	5mg	Tablets	IMAI-R	N
011	Halothane		Liquid	AB	V
042	Heparin	1000iu/ml	Injection	AB	V
042	Heparin	5000iu/ml	Injection	AB	V
043	Hepatitis B		Injection	AB	V
044	Hepatitis B Immunoglobulin		Injection	AB	V
021	Hexoprenaline	2.5mcg/ml	Injection (10ml)	AB	E
021	Hexoprenaline	2.5mcg/ml	Injection (10ml)	AB*	E
044	Human Antibody Globulin		Injection	A	E
042	Hyaluronidase	300 IU/ml	Injection (5ml)	A	N
051	Hydralazine	25mg	Tablets	AB	E
063	Hydrocortisone	1%	Ointment	AB	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
021	Hydrocortisone Sodium Succinate	100mg	Powder for Injection	ABC	V
062	Hydrogen Peroxide	6%	Solution	AB	N
051	Hydroxychloroquine	200mg	Tablets	AB	E
051	Hydroxyurea	500mg	Capsules	R	E
011	Hydroxyzine	50mg/ml	Injection (2ml)	AB	E
011	Hydroxyzine	25mg	Tablets	AB	E
021	Hyoscine Butyl Bromide	20mg/ml	Injection	AB	E
051	Hyoscine Butyl Bromide	10mg	Tablets	ABC	E
051	Ibuprofen	200mg	Tablets	IMAI-R	E
051	Ibuprofen	400mg	Tablets	IMAI-R	E
063	Ichthammol		Ointment	ABC	N
021	Ifosfamide	500mg	Powder for Injection	R	E
011	Imipramine	10mg	Tablets	AB	E
051	Indapamide	2.5mg	Tablets	AB	N
012	Indinavir	400mg	Capsules	AB	V
051	Indomethacin	25mg	Capsules	AB	E
052	Indomethacin	100mg	Suppositories	A	N
042	Insulin Zinc, Long Acting	100u/ml	Injection	A	V
042	Insulin, Isophane, Intermediate Acting	100u/ml	Injection	AB	V
042	Insulin, Soluble + Isophane (30/70)	100u/ml	Injection	AB	V
042	Insulin, Soluble, Short Acting	100u/ml	Injection	AB	V
173	Intrauterine Contraceptive Device	260mg Cu		AB	E
051	Iodine	10%	Aq. Solution	AB	N
065	Ipratropium Bromide Nebuliser Solution	0.25mg/ml	Nebuliser Solution	S	N
011	Isoflurane		Liquid	S	E
051	Isoniazid	100mg	Tablets	ABC#	V
051	Isosorbide Dinitrate	10mg	Tablets	AB	E
051	Isosorbide Dinitrate	40mg	Tablets	AB	E
051	Isotretinoin	20mg	Capsules	S	N
051	Itraconazole	100mg	Capsules	AB	E
021	Kanamycin	1g	Injection	AB	V
011	Ketamine	10mg/ml	Injection	AB	V
011	Ketamine	50mg/ml	Injection	AB	V
051	Ketoconazole	200mg	Tablets	A	E
064	Ketorolac	0.50%	Eye Drops	A	N
021	L - Asparaginase	10,000 IU/ml	Injection	R	E
002	Lactose-free Milk Supplement		Powder	AB	E
061	Lactulose	3.3g/5ml	Liquid	S	N

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
012	Lamivudine	50mg/5ml	Oral Solution	AB	V
012	Lamivudine	150mg	Tablets	IMAI-R	V
012	Lamivudine + Abacavir	30mg + 60mg	Tablets	AB	V
012	Lamivudine + Stavudine	030mg + 06mg	Tablets	AB	V
012	Lamivudine + Stavudine	060mg + 12mg	Tablets	AB	V
012	Lamivudine + Stavudine	150mg + 30mg	Tablets	IMAI-R	V
012	Lamivudine + Stavudine + Abacavir	150mg + 300mg + 300mg	Tablets	IMAI-R	V
012	Lamivudine + Stavudine + Nevirapine	030mg + 06mg + 050mg	Tablets	AB	V
012	Lamivudine + Stavudine + Nevirapine	060mg + 12mg + 100mg	Tablets	AB	V
012	Lamivudine + Stavudine + Nevirapine	150mg + 30mg + 200mg	Tablets	IMAI-R	V
012	Lamivudine + Tenofovir	300mg + 300mg	Tablets	IMAI-R	V
012	Lamivudine + Zidovudine	150mg + 300mg	Tablets	IMAI-R	V
012	Lamivudine + Zidovudine	30mg + 60mg	Tablets	AB	V
012	Lamivudine + Zidovudine + Nevirapine	150mg + 300mg + 200mg	Tablets	IMAI-R	V
012	Lamivudine + Zidovudine + Nevirapine	30mg + 60mg + 50mg	Tablets	AB	V
021	Lefolnic Acid	12.5mg	Injection	R	E
021	Lenograstim	263mg	Injection	R	E
051	Letrozole	2.5mg	Tablets	R	E
064	Levobunolol (or Alternative Beta Blocker)	0.50%	Eye Drops	AB	E
051	Levofloxacin	250mg	Tablets	AB	V
051	Levonorgestrel + Ethinyestradiol	triphasic	Tablets	ABC	N
051	Levonorgestrel + Ethinylestradiol	150mcg + 30mcg	Tablets	ABC	E
051	Levothyroxine Sodium	100mcg	Tablets	AB	E
051	Levothyroxine Sodium	50mcg	Tablets	AB	E
021	Lignocaine	1%	Injection	ABC	V
063	Lignocaine	2%	Jelly	AB	N
062	Lignocaine	100mg/g (10%)	Spray	AB	N
021	Lignocaine	2%	Dental Cartridge	AB	E
021	Lignocaine	2%	Injection (i.v.)	AB	V
021	Lignocaine + Epinephrine	2%	Dental Cartridge	AB	E
021	Lignocaine Spinal (to be mixed with 7.5% Glucose)	5%	Injection	AB	N
021	Linezolid	2mg/ml	Infusion (300ml)	R	V

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
051	Linezolid	400mg	Tablets	R	V
051	Linezolid	600mg	Tablets	R	V
061	Lipid Concentrate (med. chain & essential fatty acids)		Solution	S	N
064	Liquid Lanolin	30mg/g	Eye Ointment	AB	N
011	Lithium Carbonate	25mg	Tablets	S	E
003	Litmus Paper, Blue		Strips	AB	N
051	Loperamide	2mg	Tablets	IMAI-R	E
012	Lopinavir + Ritonavir	(400 + 100) mg/5ml	Oral Solution	AB	V
012	Lopinavir + Ritonavir	100mg + 25mg	Tablets	AB	V
012	Lopinavir + Ritonavir	200mg + 50mg	Tablets	AB	V
011	Lorazepam	1mg	Tablets	A	N
063	Lubricating Jelly		Ointment	ABC	N
021	Magnesium Sulphate	500mg/ml	Injection (2ml)	ABC	V
031	Maintenance Sol., Neon., Potassium-Free	200ml	Infusion	A	E
031	Maintenance Sol., Neonatal	200ml	Infusion	AB	E
031	Maintenance Sol., Paediatric, + 5% Dextr.	200ml	Infusion	A	E
031	Maintenance Soln. + 10% Dextrose	1,000 ml	Infusion	AB	E
031	Maintenance Soln. + 5% Dextrose	1,000 ml	Infusion	A	E
031	Mannitol 20%	200ml	Infusion	AB	E
031	Mannitol for Irrigation 5%	3,000 ml	Solution	AB	N
044	Measles Immunoglobulin		Injection	AB	V
043	Measles Vaccine		Injection	ABC	V
051	Medroxyprogesterone	5mg	Tablets	AB	E
021	Medroxyprogesterone Acetate	150mg	Injection	ABC	E
051	Mefloquine	250mg	Tablets	R	N
051	Melphalan	2mg	Tablets	R	E
043	Meningococcal Vaccine A & C		Injection	AB	V
051	Mercaptopurine	50mg	Tablets	R	E
062	Mercurochrome	1%	Solution	ABC	N
021	Meropenem	1g	Injection	S	V
021	Meropenem	500mg	Injection	S	V
021	Mesna	100mg/ml	Injection (4ml)	R	E
051	Metformin	500mg	Tablets	AB	E
012	Methadone	2mg/5ml	Syrup	AB	E
021	Methotrexate	25mg/ml	Injection (2ml)	R	E
051	Methotrexate	2.5mg	Tablets	R	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
063	Methyl Salicylate		Ointment	ABC	N
051	Methyldopa	250mg	Tablets	AB	V
021	Methylene Blue	1%	Injection	AB	E
012	Methylphenidate	10mg	Tablets	S	N
021	Methylprednisolone Sodium Succinate	1 g	Powder for Injection	AB	N
021	Metoclopramide	5mg/ml	Injection (2ml)	IMAI-R	E
051	Metoclopramide	10mg	Tablets	IMAI-R	E
021	Metronidazole	5mg/ml	Injection (100ml)	S	V
021	Metronidazole	5mg/ml	Injection (100ml)	S	V
052	Metronidazole	1g	Suppositories	AB	E
052	Metronidazole	1g	Suppositories	AB	E
061	Metronidazole	200mg/5ml	Suspension	ABC	V
061	Metronidazole	200mg/5ml	Syrup	ABC	E
051	Metronidazole	400mg	Tablets	ABC	V
051	Metronidazole	400mg	Tablets	ABC	V
063	Mexenone		Cream	ABC	N
051	Mexiletine	50mg	Tablets	S	E
011	Midazolam	5mg/ml	Injection (3ml)	S	E
002	Milk Protein Food Supplement		Powder	S	E
051	Minoxidil	10mg	Tablets	S	N
051	Minoxidil	5mg	Tablets	S	N
051	Misoprostol	200mcg	Tablets	AB*	E
042	Mitomycin (Streptomyces Caespitosis)	2mg	Powder for Injection	R	E
042	Mitoxanthrone	2mg/ml	Injection	R	E
012	Morphine Sulphate	10mg/ml	Injection	AB	V
012	Morphine Sulphate	15mg/ml	Injection	AB	V
012	Morphine Sulphate		Powder	AB	E
012	Morphine Sulphate	10mg	Slow Release Tablets	AB	E
012	Morphine Sulphate	30mg	Slow Release Tablets	AB	E
021	Moxifloxacin	400mg/250ml	Infusion	S	V
051	Moxifloxacin	400mg	Tablets	R	V
051	Multivitamin		Syrup	ABC	N
051	Multivitamin		Tablets	ABC	N
042	Multivitamin		Injection	A	E
042	Multivitamin (Vitamin A, D, K), Adults		Infusion	A	E
042	Multivitamin (Vitamin A, D, K), Paediatr.		Infusion	A	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
021	N-Acetylcysteine	200mg/ml	Injection	AB	E
061	N-Acetylcysteine	200mg/sachet	Sachet/Powder	S	N
061	Nalidixic Acid	250mg/5ml	Suspension	ABC	V
051	Nalidixic Acid	500mg	Tablets	ABC	V
021	Naloxone	0.02mg/ml	Injection	AB	V
021	Naloxone	0.4mg/ml	Injection	AB	V
064	Natamycin	5%	Eye Drops	S	N
021	Neostigmine	2.5mg/ml	Injection	AB	V
012	Nevirapine	50mg/5ml	Suspension	AB	V
012	Nevirapine	200mg	Tablets	IMAI-R	V
051	Nicotinamide	50mg	Tablets	AB	E
051	Nifedipine	5mg	Capsules	S	E
051	Nitrofurantoin	100mg	Capsules	AB	E
	Nitrous Oxide		Gas	AB	V
051	Norethisterone	0.35mg	Tablets	ABC	E
021	Norethisterone Enanthate	200mg/ml	Injection	ABC	E
051	Norgesterel + Ethinylestradiol	500mcg + 50mcg	Tablets	ABC	N
002	Nutrient Denser Follow up Formula		Powder	AB	E
002	Nutritional Supplement		Powder	AB	V
063	Nystatin	100,000 units/g	Topical Cream	AB	E
051	Nystatin	100,000 units	Uncoated Tablets	ABC	E
061	Nystatin	100,000 units/ml	Oral Suspension	ABC	E
063	Nystatin Topical	100,000 IU/g	Cream	AB	E
064	Ofloxacin	0.3%	Eye Drops	R	E
011	Olanzapine	10mg	Tablets	S	E
051	Omeprazole	20mg	Capsules	AB	E
021	Ondansetron	2mg/ml	Injection (4ml)	R	E
051	Ondansetron	8mg	Tablets	R	E
063	Oral Anaesthetic Gel		Oral Gel	AB	N
001	Oral rehydration salts (WHO formula)		Powder	ABC	V
042	Ornipressin	5 IU/ml	Injection	S	E
051	Oxatamide	30mg	Tablets	S	N
064	Oxybuprocaine	0.40%	Eye Drops	AB	E
	Oxygen		Gas	ABC	V
064	Oxymetazoline	0.05%	Drops	S	N
064	Oxymetazoline	Paed. 0.025%	Eye Drops	ABC	N
042	Oxytocin	10 IU/ml	Injection	AB	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
042	Oxytocin	5 IU/ml	Injection	AB*	V
001	p-Amino Salicylic Acid	4g	Sachet	S	V
051	Pancrelipase	234.2mg	Capsules	S	N
042	Pancuronium Bromide	2mg/ml	Injection (2ml)	A	E
003	Pap Smear Fixative			ABC	E
021	Paracetamol	1g/100ml	Infusion	AB	V
021	Paracetamol	500mg/50ml	Infusion	AB	V
061	Paracetamol	120mg/5ml	Syrup	ABC	E
051	Paracetamol	500mg	Tablets	ABC	E
051	Paracetamol + Codeine Phosphate	500mg + 8mg	Tablets	AB	N
051	Penicillamine, d-	125mg	Tablets	S	E
051	Perindopril (or Alternative)	4 mg	Tablets	ABC#	E
031	Perit. Dialysis Soln+Dextrose 4.25%; 1L in 2L Spike		Solution	AB	V
031	Perit. Dialysis Soln+Dextrose 4.25%; 2L in 3L Luer		Solution	A	
031	Peritoneal Dialysis Solution + Dextrose 2%; 1L in 2L Spike		Solution	AB	V
031	Peritoneal Dialysis Solution + Dextrose 2%; 2L in 3L Luer		Solution	A	
063	Permethrin	5%	Cream	R	N
012	Pethidine Hydrochloride		Injection	AB	E
011	Phenobarbitone	200mg/ml	Injection	AB	E
011	Phenobarbitone	15mg/5ml	Syrup	ABC#	E
011	Phenobarbitone	15mg	Tablets	ABC#	E
011	Phenobarbitone	30mg	Tablets	ABC#	E
061	Phenoxymethylpenicillin	250mg/5ml	Syrup	ABC	V
051	Phenoxymethylpenicillin	250mg	Tablets	ABC	V
064	Phenylephrine	3%	Eye Drops	A	E
021	Phenytoin	250mg/5ml	Injection	AB	E
061	Phenytoin	125mg/5ml	Suspension	AB	E
051	Phenytoin	100mg	Tablets	ABC#	V
061	Phosphate Comp.		Enema	AB	E
021	Phytomenadione	10mg/ml	Injection	AB	E
021	Phytomenadione	2mg/ml	Injection (0.5ml)	AB*	V
064	Pilocarpine	2%	Eye Drops	AB	E
011	Pimozide	1mg	Tablets	S	N
021	Piperacillin + Tazobactam	4g + 500mg	Powder for Injection	S	E
031	Plasmolyte B	1,000 ml	Infusion	ABC	V
031	Plasmolyte B	200ml	Infusion	AB	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
062	Podophyllin	15%	Paint	AB	E
043	Poliomyelitis (oral, with dropper)		Oral Vaccine	ABC	V
061	Polymeric Adult Feeds (ready to hang) e.g. Fresubin Original		Solution (1000ml)	S	V
061	Polymeric Paediatric Feeds (ready to hang) e.g. Nutren Junior ready to drink	Suitable for children 1-10 year old	Solution	S	V
021	Potassium Chloride	15%	Injection	AB	V
051	Potassium Chloride	600mg	Slow Release Tabs	AB	E
061	Potassium Citrate		Solution	ABC	N
063	Povidone - Iodine	10%	Ointment	ABC	E
062	Povidone - Iodine	7.5%	Scrub	ABC	N
062	Povidone - Iodine	10%	Solution	IMAI-R	E
052	Povidone - Iodine	200mg	Pessaries	S	N
051	Praziquantel	600mg	Tablets	AB	V
064	Prednisolone	10%	Eye Drops	R	E
051	Prednisone	50mg	Tablets	S	E
051	Prednisone	5mg	Tablets	AB	V
042	Pre-filled 3-chamber TPN Bag with Electrolytes		Infusion (2/3L)	S	E
041	Pregnancy Diagnostic Kit (HCG)			ABC	N
002	Premature Feeding Formula		Powder	AB	V
061	Premature Infant Formula (ready to drink) e.g. Pre-NAN		Solution	S	V
051	Probenecid	500mg	Tablets	AB	E
021	Procaine Benzyl Penicillin	3g (3 million IU) or 300mg/ml	Powder for Injection (10ml)	ABC	V
051	Procarbazine	50mg	Tablets	R	E
011	Prochlorperazine	12.5mg	Injection	S	E
011	Prochlorperazine	12.5mg/ml	Injection	AB	E
051	Proguanil	100mg	Tablets	ABC	E
011	Promethazine	25mg/ml	Injection	AB	V
011	Promethazine	25mg/ml	Injection	AB	V
062	Promethazine	5mg/5ml	Syrup	AB	E
061	Promethazine	5mg/5ml	Syrup	AB	E
051	Promethazine	10mg	Tablets	AB	E
051	Promethazine	10mg	Tablets	AB	E
011	Propofol	10mg/ml	Injection	AB	E
021	Propranolol	1mg/ml	Injection	AB	E
051	Propranolol	10mg	Tablets	AB	E
051	Propranolol	40mg	Tablets	AB	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
047	Prostaglandin E2	1mg/3g	Gel	S	E
021	Protamine Sulphate	1%	Injection	AB	E
021	Protamine Sulphate	10mg/ml	Injection	AB	E
051	Pyrazinamide	500mg	Tablets	ABC#	V
051	Pyridostigmine	60mg	Tablets	S	N
051	Pyridoxine Hydrochloride (Vitamin B6)	25mg	Tablets	ABC#	E
051	Pyrimethamine + Sulphadoxine	25mg + 500mg	Tablets	ABC	E
021	Quinine Dihydrochloride	300mg/ml	Injection	AB	V
051	Quinine Sulphate	300mg	Tablets	AB	V
044	Rabies Immunoglobulin		Injection	AB	V
043	Rabies Vaccine (Cell Culture Vaccine)		Injection	ABC#	V
021	Ranitidine	25mg/ml	Injection (2ml)	A	E
051	Ranitidine	150mg	Tablets	AB	E
001	Ready to use Supplementary Therapeutic Food	92g, 500kcal	Sachet	AB*	E
001	Ready to use Therapeutic Food (RUTF) Plumpy Nut	92g, 500kcal	Sachet	AB*	E
002	Realimentation Powder for Infant Diarrh.		Powder	S	V
051	Retinol (Vitamin A)		Capsules	ABC	V
051	Rifampicin	150mg	Capsules	ABC#	V
061	Rifampicin	100mg/5ml	Syrup	ABC#	V
051	Rifampicin	450 mg	Tablets	ABC#	V
051	Rifampicin	450mg	Tablets	ABC#	V
061	Rifampicin + Isoniazid	150mg +75mg	Tablets	ABC	V
061	Rifampicin + Isoniazid	60mg +30mg	Tablets	ABC#	V
061	Rifampicin + Isoniazid + Ethambutol	150mg + 75mg + 275mg	Tablets	ABC#	V
061	Rifampicin + Isoniazid + Pyrazinamide	60mg +30mg +150mg	Tablets	ABC#	V
061	Rifampicin + Isoniazid + Pyrazinamide + Ethambutol	150mg + 75mg + 400mg + 275mg	Tablets	ABC	V
031	Ringers Lactate	1,000 ml	Infusion	ABC	V
011	Risperidone	1mg	Tablets	S	E
011	Risperidone	2mg	Tablets	S	E
012	Ritonavir	100mg	Capsules	AB	V
042	Rituximab	100mg/10ml	Concentrate for solution for infusion	S	E
042	Rocuronium	50mg/5mL	Injection (5ml)	A	E
061	Salbutamol	2mg/5ml	Syrup	AB	E
051	Salbutamol	2mg	Tablets	AB	V
065	Salbutamol	500mcg/ml	Injection	AB	V

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
065	Salbutamol MDI or powder for inhalation	100mcg/dose	Inhaler	ABC	E
065	Salbutamol solution for inhalation	5mg/ml (0.5%)	Nebuliser Solution	ABC	V
001	Salicylic Acid		Powder	AB	N
044	Scorpion Antiserum		Injection	AB	V
061	Semi Elemental Adult Feeds (ready to hang) e.g. Peptamen Neutral Dual		Solution (500ml)	S	V
061	Semi Elemental Paediatric Feeds (ready to hang) e.g. Peptamen Junior AdvanceNeutral Dual	NB: Suitable for children 1-10 year old	Solution (500ml)	S	V
061	Sennosides A+B	142mg/71ml	Liquid	AB	E
011	Sevoflurane		Liquid	A	N
001	Silver Nitrate		Pencil	AB	N
063	Silversulfadiazine	1%	Ointment	AB	E
051	Simvastatin	20mg	Tablets	S	E
051	Simvastatin	40mg	Tablets	S	E
044	Snake Venom Antiserum Polyvalent		Injection	ABC	V
001	Soda Lime with Indicator		Powder	AB	
021	Sodium Bicarbonate	4%	Injection	AB	V
021	Sodium Bicarbonate	8%	Injection	AB	V
031	Sodium Bicarbonate 4.2%	500ml	Infusion	A	E
021	Sodium Chloride	20%	Injection	A	E
031	Sodium Chloride 0.45%	1,000 ml	Infusion	AB	E
031	Sodium Chloride 0.9%	1,000 ml	Infusion	ABC	V
031	Sodium Chloride 0.9%	200ml	Infusion	AB	E
031	Sodium Chloride 0.9%	50ml	Infusion	A	N
031	Sodium Chloride 0.9%	3,000ml	Solution	S	N
031	Sodium Chloride 0.9% in Pour Bottles	1,000 ml	Solution	AB	N
031	Sodium Chloride 5%	200ml	Infusion	AB	E
065	Sodium Chromoglycate MDI or Powder for Inhalation	5mg/dose	Inhaler	S	N
064	Sodium Cromoglycate	2%	Eye Drops	R	N
064	Sodium Cromoglycate	4%	Eye Ointment	S	N
042	Sodium Hyaluronate	10mg	Injection	S	N
062	Sodium Hypochlorite (stabilised, sterilising fluid)		Solution	ABC	E
001	Sodium Polystyrene Sulfonate		Resin	S	N
002	Soya Protein Milk Substitute		Powder	A	E
061	Special Immune Modulating Adult Feeds (ready to hang) e.g. Impact entral neutral dual		Solution	S	E
061	Specialized Pharmaco- nutrients e.g. Intes-tamin		Solution	S	E

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
044	Spider Venom Antiserum		Injection	AB	V
062	Spirits, Methylated		Solution	ABC	E
051	Spironolactone	25mg	Tablets	AB	E
012	Stavudine	15mg	Capsules	AB	V
012	Stavudine	20mg	Capsules	AB	V
012	Stavudine	30mg	Capsules	AB	V
012	Stavudine	1mg/ml	Liquid	AB	V
031	Sterile Water for Irrigation	3,000ml	Solution	S	N
021	Streptomycin	1g	Powder for Injection	ABC#	V
061	Sucralfate	1g/5ml	Suspension	S	E
051	Sulphasalazine	500mg	Tablets	A	E
011	Sulpiride	50mg	Tablets	AB	E
042	Suxamethonium Chloride	50mg/ml	Injection (2ml)	AB	E
051	Tamoxifen	20mg	Tablets	R	E
012	Tenofovir	300mg	Tablets	IMAI-R	V
012	Tenofovir + Emtricitabine	300mg+200mg	Tablets	IMAI-R	V
012	Tenofovir + Emtricitabine + Efavirenz	300mg+200mg+600mg	Tablets	IMAI-R	V
063	Terbinafine	1%	Cream	S	N
044	Tetanus Immunoglobulin	250 IU/ml	Injection	AB	V
044	Tetanus Immunoglobulin	500 IU/ml	Injection	AB	V
043	Tetanus Toxoid (adsorbed)		Injection	ABC	V
064	Tetracycline *	1%	Eye Ointment	AB	E
051	Theophylline Anhydrous	200mg	Slow Release Tabs	ABC#	E
061	Theophylline Oral Solution (alcohol free)	5mg/ml	Solution	ABC#	E
001	Therapeutic complex of Minerals and Vitamins			AB	E
051	Thiamine (Vitamin B1)	100mg	Tablets	AB	E
021	Thiamine Hydrochloride (Vitamin B1)	100mg/ml	Injection	A	N
051	Thioguanine	40mg	Tablets	R	E
011	Thioridazine	100mg	Tablets	S	E
011	Thioridazine	25mg	Tablets	S	E
012	Tilidine	50mg/0.5ml	Drops	AB	N
	Total Phospholipids	25mg/ml	Suspension	AB	E
011	Tramadol Hydrochloride	50mg/ml	Injection (2ml)	AB	N
011	Tramadol Hydrochloride	50mg	Tablets	AB	N
021	Tranexamic Acid	100mg/ml	Injection	AB	E
051	Tranexamic Acid	500mg	Tablets	S	N
042	Trastuzumab	440mg	Powder for Injection	S	E
063	Tretinoin	0.05%	Cream	S	N

CMS	MEDICINE	STRENGTH	DOSAGE FORM	LEVEL	VEN
011	Trihexyphenidyl (Benzhexol)	2mg	Tablets	S	N
011	Trihexyphenidyl (Benzhexol)	5mg	Tablets	S	N
011	Trimipramine	25mg	Tablets	A	E
041	Tuberculin as MANTOUX (diagnostic)		Injection	AB	E
043	Typhoid		Injection	A	V
062	Ultrasound Gel		Gel	AB	
003	Urine Test Strip (Glucose, Prot, pH, Ket., Blood)		Strips	ABC	E
003	Urine Test Strip (Glucs, Prot., pH, Ket., Blood,Nitr., Bili., Urobil.)		Strips	AB	E
051	Valproate, Sodium	200mg	Tablets	AB	N
061	Valproate, Sodium + Valproic acid CR	333mg + 145mg	Tablets	AB	N
061	Valproic Acid	200mg/5ml	Solution	AB	N
051	Valsartan	80mg	Tablets	A	E
021	Vancomycin	1g	Injection	S	V
021	Vancomycin	500mg	Injection	S	V
044	Varicella Zoster Immunoglobulin		Injection	S	E
021	Verapamil	2.5mg/ml	Injection (2ml)	AB	N
051	Verapamil	40mg	Tablets	AB	E
051	Verapamil	80mg	Tablets	AB	E
042	Vinblastine	10mg	Powder for Injection	R	E
042	Vincristine	1mg	Powder for Injection	R	E
021	Voriconazole	200mg/ml	Injection	R	E
051	Warfarin Sodium	5mg	Tablets	AB	V
021	Water for Injection	10ml	Injection	ABC	V
021	Water for Injection	5ml	Injection	ABC	V
031	Water for Irrigation in Bags	1,000 ml	Solution	AB	N
031	Water for Irrigation in Pour Bottle	1,000 ml	Solution	ABC	N
064	Wax Softening Solution (* NOT for take home)		Ear Drops	ABC	N
002	Whey Predominant Starter Formula		Powder	AB	N
043	Yellow Fever		Injection	A	V
012	Zidovudine	50mg/5ml	Syrup	AB	V
012	Zidovudine	100mg	Tablets	AB	V
012	Zidovudine	300mg	Tablets	IMAI-R	V
061	Zinc (as sulphate)	10mg/5ml	Liquid	ABC	E
051	Zinc (as sulphate)	10mg	Tablets	ABC	E
051	Zinc (as sulphate)	20mg	Tablets	ABC	E
063	Zinc Cream		Cream	ABC	N
011	Zuclopenthixol acetate	50mg/ml	Injection	A	E

ANNEX 1

OVERVIEW OF PROCESSES FOR REQUESTING, AND EVALUATING APPLICATIONS FOR, CHANGES TO THE NEMLIST OR BUY-OUT ITEMS

Activity	Responsible	Tasks	Tools/ Resources
<p>Submission of motivations for changes to the Nemlist</p> <ul style="list-style-type: none"> • Addition • Deletion • Replacement • Reclassification 	<ol style="list-style-type: none"> 1. Individual health worker 2. Hospital departments 3. Programs/ program managers 4. District therapeutic committees 5. Regional therapeutic committees 	<ol style="list-style-type: none"> 1. Compiles required data/information and supporting documentation for the motivation 2. Prepares submission documents (Request form, appendices/ annexes with supporting materials) 3. Submits request to <ol style="list-style-type: none"> a. District/facility therapeutics committee (If from an individual health worker or hospital department) b. EMLC secretariat (If from a regional/district therapeutics committee or program) 	<ol style="list-style-type: none"> 1. Instructions for submitting requests for changes to the Nemlist 2. Application form for requesting changes to the Nemlist
<p>Submission of motivations for buy-outs</p>	<ol style="list-style-type: none"> 1. Individual health worker 2. Hospital department 	<ol style="list-style-type: none"> 1. Compiles data and prepares submission documents as above 2. Submits request to district/facility therapeutics committee 	<ol style="list-style-type: none"> 1. Instructions for requesting procurement of a non-Nemlist medicine 2. Application form for buyouts

Activity	Responsible	Tasks	Tools/ Resources
<p>Receipt and processing of motivation</p> <p>1. Nemlist Applications</p>	<p>1. EMLC Secretariat</p>	<p>Responsible staff receives submission documents</p> <p>Responsible staff checks submitted documents to verify that all the required information (fields) are completed</p> <ol style="list-style-type: none"> 1. For EMLC submissions <ol style="list-style-type: none"> a. If documentation is acceptable, the responsible staff formally acknowledges receipt of submitted documents for EMLC consideration by communicating this in writing to the motivator. <p><i>If the documentation is not acceptable, the EML Secretariat will write to the motivator and request him/her to make the changes required in the motivation.</i></p> b. Responsible staff enters information about the accepted motivation in the formulary tool/register c. Responsible staff sends the motivation document(s) to the competent technical person who will evaluate the motivation 	<ol style="list-style-type: none"> 1. Checklist of required data/information that should be in the submitted information 2. Formulary tool or register for motivations or buyout requests

Activity	Responsible	Tasks	Tools/ Resources
2. Buyout applications	2. Hospital/ Regional Pharmacist or Pharmacist's Assistant	2. For buy-out requests a. Responsible staff verifies documents and if acceptable, sends the document for evaluation by the regional/hospital pharmacist as appropriate.	
Evaluation of motivation 1. Nemlist Applications 2. Buyout Applications	1. E M L C technical staff 2. Regional/ Hospital Pharmacist	1. Technical evaluator reviews motivation and related documentation for completeness 2. Technical evaluator carries out literature review on safety and efficacy comparing the motivation medicine with existing Nemlist alternative(s) 3. Technical evaluator carries out analysis of cost comparing the motivation medicine with existing Nemlist alternative(s) 4. Technical evaluator carries out analysis of other potentially relevant considerations such as registration status, product quality assurance and health/ pharmaceutical issues.	1. Technical guidelines for evaluating requests for changes to the Nemlist/buy-outs 2. Checklist of data sources and resources 3. Template for evaluation summary 4. Template for summary table of motivations for EMLC discussion and decision making.

Activity	Responsible	Tasks	Tools/ Resources
<p>3. Buy-out Application</p> <ul style="list-style-type: none"> • Approve • Reject • Defer decision 	1. District/ Regional TC for buy-out requests	2. EMLC/TC secretary records decision and it rationale	
<p>Communication of EMLC/ TC decision</p> <p>1. Nemlist applications</p> <p>2. Buyout applications</p>	<p>1. EMLC Secretariat</p> <p>C. TC Secretary</p>	<p>For EMLC decisions, the EMLC secretariat</p> <p>A. Presents EMLC recommendations to the PMDRC for approval</p> <p>B. Prepares written communication to the motivator regarding EMLC decision</p> <p>For TC decisions, the TC secretary communicates decision to</p> <p>a. Motivator</p> <p>b. The DCC/ economizing committee (Approvals for buy-outs)</p>	1. Template for presenting EMLC decisions to the PM-DRC
Communication of PMDRC approvals to Regional and National Directorates facilities	NMPC	<p>1. NMPC prepares circular on approved changes for distribution to facilities through the PS</p> <p>2. NMPC prepares updated/ revised Nemlist as appropriate</p>	

ANNEX 2:

SUMMARY OF TECHNICAL GUIDELINES FOR EVALUATING REQUESTS FOR CHANGES TO THE NEMLIST/BUYOUTS

PURPOSE

This document provides guidelines to evaluators on the procedures to be followed in assessing applications for changes to the Nemlist or requests for procurement of non-Nemlist medicines.

PRINCIPLES

1. Selected medicines shall satisfy the priority health care needs of the population. Prioritization of health problems shall be based on current morbidity and mortality data.
2. New medicines shall substitute existing medicines and/or be added to the Nemlist only if there is documented evidence of clinical and cost benefit.
3. For two or more medicines of similar safety and efficacy profiles, selection will consider the comparative costs of the treatment regimens
4. Selected medicines should be formulated as single compounds. Combination products may be included if:
 - i. The active ingredients act synergistically and are proven to be superior over single compounds administered separately.
 - ii. There is evidence that the combination product improves adherence.
5. All medicines are to be identified by either their international non-proprietary name (INN) or generic name.

PROCEDURES

A. Literature review to assess evidence base for safety and efficacy.

1. Perform a literature review to establish the following about the medicine:
 - i. Efficacy/comparative efficacy with existing Nemlist and/or therapeutic group alternatives
 - ii. Effectiveness/comparative effectiveness with existing Nemlist and/or therapeutic group alternatives
 - iii. Safety/comparative safety
 - iv. Cost effectiveness

2. Critically appraise clinically relevant studies from literature sources and provide recommendations based on the strength of evidence and clinical significance.
3. Review literature sources in the following hierarchical order starting from tertiary sources moving up to primary sources if necessary.
 - i. Medicine and therapeutic textbooks
 - ii. Published guidelines
 - iii. Drug bulletins
 - iv. Systematic reviews/meta-analyses
 - v. Clinical trials/studies

B. Supply Chain and Cost Consideration

1. Registration status in Namibia

Determine the registration status of the proposed medicine in Namibia from the NMRC database¹. Registered medicines shall be prioritized for inclusion in the Nemlist over the others as their efficacy and safety data has already been reviewed by the NMRC.

2. Cost of treatment²

Determine the following for the proposed medicine (as well as the Therapeutic and Nemlist alternatives if any are available):

- i. Cost of treatment/patient/day & the cost of a course of treatment (e.g. for chemotherapy agents)
- ii. Estimated number of patients requiring the treatment per annum
- iii. Estimated annual cost/Implications for annual budget or financing for the medicine

3. Storage and handling requirements³

Determine whether the proposed medicine:

- i. Has special storage requirements e.g. cold chain requirement
- ii. Has special handling requirements e.g. extemporaneous preparation at the hospital pharmacy which would require specific materials and equipment

C. Assigning the secretariat/evaluators recommendations to the EMLC

Based on the finding of the evaluations above, the secretariat shall prepare a summary of findings and recommendations in a tabular form for deliberations by the EMLC. The Secretariat's recommendations shall be summarized as follows⁴:

¹ This database may be obtained from the Registrar of Medicines or accessed at www.nmrc.com.na

² Sources of these data may include:

- i. The motivation
- ii. CMS price guide
- iii. Private sector price quotations
- iv. International price guides

³ This data may be obtained from product specification data/ compendia

⁴ Adapted from Ansani, N.T., Fedutes-Henderson, B.A., Skledar, S.J., Branch, R., Sirio, C.A., Smitherman, T. & Weber, R.J. (2005). Practical Approach to Grading Evidence for Formulary Recommendations. *Am J Health Syst Pharm*, 62: 1498-1501



1. **1A**= Add to the Nemlist/Reclassify/Replace as requested.
2. **1B**= Add to the Nemlist/ Reclassify/Replace as requested BUT review relevant literature, use and outcomes yearly.
3. **2A**= Deny/reject request for Addition/ Reclassification/ Replacement.
4. **2B**= Deny/reject request for Addition/Reclassification/Replacement BUT review if there is additional evidence or information



ANNEX 3

GUIDELINES FOR SUBMITTING REQUESTS FOR CHANGES TO THE NEMLIST AND

NAMIBIA STANDARD TREATMENT GUIDELINES

Purpose

This document provides guidelines for the submission of requests for changes to the Namibia Essential Medicines List (Nemlist). The form can also be used for requesting for changes to the Namibia Standard Treatment Guidelines (STGs)

Procedures

1. Fully complete Sections A and C of the “**Request Form for Changes to the Nemlist**”, Annex 4 of the Nemlist. (*See details below*)
2. Attach copies of publications, scientific articles or guidelines to support the request.
3. Provide your full contact details including position, institution and telephone/Email address
4. Submit the completed documents to
 - i. District/Regional/Windhoek Hospitals therapeutics committees- For individual health workers, hospital departments
 - ii. EMLC secretariat- For programmes/programme managers or for motivations originating from Regional therapeutics committees

Completing the request form for changes to the Nemlist

Section A: Details of the applicant and application- *indicate the following*

- i. Name, designation, contact details, health facility or program, region and signature of the applicant
- ii. Date of application
- iii. Whether the application has been reviewed by the district or regional TC (or the health program where applicable) before submission to the EMLC
- iv. Whether the change proposed affects the Nemlist, the STGs or both documents

The EMLC will acknowledge all submissions and communicate decisions with supporting arguments where appropriate. The requestor may also be contacted for additional information to support the application.



Section B: For requests for changes to the STGs

- i. Indicate the section, sub-section and page number(s) in the STG that are proposed to be changed. If it is an entirely new section of the STG, indicate this on the form
- ii. Describe the changes you would like made on the STGs
- iii. Provide reasons for the requested changes and list the publications or sources supporting your proposed changes. If possible, attach the supporting documents.

Section C: For requests for changes to the Nemlist

1 Nature of request- *tick in the appropriate box*

- i. **Addition**- Inclusion of a new medicine on the list
- ii. **Deletion**- Removal of a medicine from the list
- iii. **Replacement**- Substitution of a medicine on the list with another one
- iv. **Reclassification**- Changing the level of care at which a medicine will be available for prescription and use

2 Details of the medicine.

Indicate

- i. The generic or the International Non-proprietary Name (INN) of the medicine identifying the pharmaceutical substance or active ingredients
- ii. Strength and formulation

3 For requests for additions

The requestor must provide the following details

- i. Indication for use- As most medicines have numerous indications, it is important to state the proposed indication for the medicine for the request. This will serve to identify the comparison medicine (s) in the current Nemlist as well as highlighting which of the potential indications you feel merit consideration.
- ii. Suggested level of care/availability- Indicate suggested users or level of care at which the medicine is to be made available (*Tick the appropriate box*)

S - Specialists only. Referral hospital level

AB- District hospital level/ to be prescribed by an MO

AB*- Primary Health Care facilities conducting deliveries

ABC#- Permitted in Primary Health Care facilities for follow-up treatment in accordance to a prescription written by a medical officer

ABC- Primary Health Care level (can be prescribed by any competent prescriber)

ABC-R-

R- Restricted Use- Available at specified levels with stated restrictions or conditions on use

IMAI-R- Available at clinics and health centres that have staff that have been trained in IMAI. They can also be stocked at District Hospital levels and above, and used as normal AB class items in these facilities

4 For requests for changing level of availability

Provide details of the medicine (generic name, strength and form), current level of care/availability, the proposed level of care/availability and the indication(s) for use for the medicine.

5 Proposed restrictions (for R class medicines)

Indicate restrictions to be applied to the medicine. This may include the specific conditions for which the medicine is to be prescribed, accountability measures (e.g. use of registers) or specific security measures. Also include the level at which the item may be stocked.

6 Reasons for request and evidence

State the reasons for the request for change and include supporting evidence such as list of publications/ references. **Please attach copies wherever possible.** Reasons for request may include consideration of the following:

- i. Therapeutic benefits and risks
- ii. Efficacy or safety profile
- iii. Cost
- iv. Available alternatives
- v. Changes in morbidity
- vi. Changes in treatment guidelines or policy

Evidence is required to support claims of: *Relative efficacy*, *Relative safety* and *Pharmacoeconomic benefit*

Section D: Decision of the EMLC

This section will be completed by the EMLC secretariat indicating whether an application has been approved/ rejected/deferred, the level of availability/care, restrictions for use if any, and the reasons for the decision.



ANNEX 4

REQUEST FORM FOR CHANGES TO THE NAMIBIA STANDARD TREATMENT GUIDELINES (STGs) AND THE NAMIBIA ESSENTIAL MEDICINES LIST (NEMLIST)

Notes:

- Section A should be completed by the applicant who may be the secretary of the District or Regional Therapeutics Committee (TC), a Program Officer in any of the health programs e.g. Malaria, TB or HIV, or an individual health worker. It is recommended that motivations by individual health workers be discussed and approved in the relevant district or regional TC
- Section B should be completed for requests for changes to the Standard Treatment Guidelines (STGs). The changes requested may be to any of the STG sections e.g. investigations or management for specific conditions. If the proposed changes to the STG will require a change in the Nemlist e.g. addition, deletion or re-classification of a medicine, the applicant must also fill out Section B.
- Section C should be completed for requests for changes to the Namibia Essential Medicines List (Nemlist) i.e. addition, deletion, replacement or reclassification of a medicine.

A separate form should be filled out for each medicine recommended for addition, deletion or re-classification on the Nemlist.

A. SECTION A: TO BE COMPLETED BY THE APPLICANT

(e.g. prescriber, pharmacist, therapeutics committee secretariat)

1. Applicant Details	
Name of person completing this form:	
Designation (e.g. Regional Pharmacist, PMO etc.):	
E-mail address of person completing this form:	
Phone number of person completing this form:	
Name of health facility (e.g. Outjo district hospital) or program (e.g. Malaria program, TB program etc.):	
Name of region:	
Signature of applicant:	
Date:	
2. Has the motivation been reviewed and approved by (attach minutes of meeting):	
The district TC?	Yes <input type="radio"/> No <input type="radio"/>
The regional TC?	Yes <input type="radio"/> No <input type="radio"/>
The health program	Yes <input type="radio"/> No <input type="radio"/>
3. Request for changes to: (tick all that apply)	
<input type="checkbox"/> Namibia Standard Treatment Guidelines (STGs)	<input type="checkbox"/> Namibia Essential Medicines List (Nemlist)

Send completed form to: Chief Pharmacist, Sub division: NMPC; Division: Pharmaceutical Services

Fax: 061 234136

E-mail: chiefpharmacist@nmpc.com.na



B. SECTION B: FOR REQUESTS FOR CHANGES TO THE STGs

1.	Indicate the section, sub section and page number in the STG that you propose to be changed
	Section of STG (e.g. <i>Section 12.5.1 Scabies</i>):
	Sub-section (e.g. <i>Management</i>):
	Page Number (e.g. <i>450</i>):
2.	If it is a new section you propose to be added to the STGs, indicate the name of this section:
3.	Request for the following changes to be made to the STG: (<i>Briefly describe below the changes you propose to the STG</i>)
4.	Reasons for request (<i>Briefly describe below the reasons for the request for the proposed change, e.g. emergence of new evidence, change in policy</i>)
5.	Evidence (<i>list the publications or sources supporting your proposed changes below; also attach the supporting documents where possible e.g. articles from journals, reports etc. The Therapeutics Information and Pharmacovigilance Centre (TIPC) may be contacted for assistance in providing supporting evidence..(Phone: 061 203 2312; e-mail: info@tipc.com)</i>)

Send completed form to: Chief Pharmacist, Sub division: NMPC; Division: Pharmaceutical Services

Fax: 061 234136

E-mail: chiefpharmacist@nmpc.com.na

D. SECTION D: DECISION BY THE EMLC *(to be completed by the STG/
EMLC secretariat)*

STG/ EMLC Secretariat Recommendations	
For requested change to STGs	<input type="radio"/> 1A = Accept proposed change to STG <input type="radio"/> 1B = Accept proposed change to STG and review relevant literature, use and outcomes yearly <input type="radio"/> 2A = Deny/reject proposed change to STG <input type="radio"/> 2B = Deny/reject proposed change to STG but review if/when there is additional evidence or information
Reason for decision:	
For requested change to Nemlist	<input type="radio"/> 1A = Add to the Nemlist <input type="radio"/> 1B = Add to the Nemlist and review relevant literature, use and outcomes yearly <input type="radio"/> 2A = Deny/reject request for addition to the Nemlist. <input type="radio"/> 2B = Deny/reject request for addition to the Nemlist but review if/when there is additional evidence or information
Reason for decision	
STG/ EML Committee Decision	
For requested change to STGs	<input type="radio"/> 1A = Accept proposed change to STG <input type="radio"/> 1B = Accept proposed change to STG and review relevant literature, use and outcomes yearly <input type="radio"/> 2A = Deny/reject proposed change to STG <input type="radio"/> 2B = Deny/reject proposed change to STG but review if/when there is additional evidence or information
Reason for decision:	
For requested change to Nemlist	<input type="radio"/> 1A = Add to the Nemlist <input type="radio"/> 1B = Add to the Nemlist and review relevant literature, use and outcomes yearly <input type="radio"/> 2A = Deny/reject request for addition to the Nemlist. <input type="radio"/> 2B = Deny/reject request for addition to the Nemlist but review if/when there is additional evidence or information
Reason for decision	
References used by the Secretariat	

Name

EMLC Chairperson

Signature

Date:

Name

EMLC Secretariat

Signature

Date:

ANNEX 5:

GUIDELINES FOR REQUESTING PROCUREMENT OF A NON-NEMLIST MEDICINE (BUY-OUT)

Purpose

This document provides guidelines to districts/ regions for requesting non-Nemlist or buy-out medicines.

Background

All medicines deemed to be essential for treatment and management of priority health problems in the country are listed in the Namibia Essential Medicines List (Nemlist).

- These medicines have been selected with due regard to the public health needs of the country, evidence on efficacy and safety and comparative cost-effectiveness.
- These medicines will be made available for use in public health facilities in accordance with the approved level of care/availability through procurement and supply by the Central Medical Stores
- Medicines not listed on the Nemlist are not available through CMS. Health facilities requiring these medicines are required to follow these guidelines when making buy-outs for the same.
- In order to monitor the buy-out situation, Regional Pharmacists are required to report the requests to the Deputy Director: Pharmaceutical Services, including the motivation for each request.
- If a particular medicine is required for regular use or is required frequently, then an application for the inclusion of the medicine on the Nemlist should be made following the prescribed procedures.

Procedures

1. Fully complete the motivation form for procurement of non-Nemlist medicines. This should include
 - i. Name, form and strength of the medicine
 - ii. Dose and duration of treatment
 - iii. Explanation why currently available medicines cannot be used
 - iv. Number of patients requiring this medicine each month
 - v. Criteria to be used to determine which patients receive the medicine
 - vi. Any other relevant information to support the application
2. Provide/ attach supporting evidence for the request. This should include
 - i. Supporting literature for use of the requested medicine
 - ii. Microscopy, culture and sensitivity results if necessary

- iii. Patient clinical details e.g. results of renal or liver function tests that support the request for alternative medicine other than what is available on the Nemlist
 - iv. If the request for the medicine is due to failed therapy, a summary of the patient's medication history and outcome(s) should be attached to support the application.
3. Obtain approval for the motivation from a specialist if necessary
 4. Submit the completed documents (Motivation form, prescription & any other supporting documents) to the pharmacy.
 5. Hospital Pharmacist evaluates request and submits it for discussion by the district TC (**see Technical guidelines for evaluating requests for changes to the Nemlist or buyouts**)
 6. The district TC reviews the motivation and approves/does not approve the request. The motivation can be referred back to the requesting officer for additional evidence.
 7. The district TC forwards the approved motivation through the Principal Medical Officer to the Regional Pharmacist (**See technical guidelines for evaluating requests for changes to the Nemlist or buyouts**)
 8. The Regional Pharmacist evaluates the request and submits it for discussion by the Regional TC.
 9. The Regional TC reviews the request and approves/does not approve the application. The application can be referred back to the requesting officer/district TC.
 10. The regional pharmacist/hospital pharmacist obtains at least three quotations from suppliers for the item.
 11. The regional pharmacist/hospital pharmacist submits the completed documents (prescription, motivation & quotations) to the economizing committee for discussion and approval for procurement.
 12. The accounts department prepares a purchase order for the requested medicine, which is sent to the selected supplier.

ANNEX 6

APPLICATION FORM FOR BUYOUTS

Motivation to buy out a non-Nemlist Medicine

Please complete the following information in as much detail as possible. This will assist in rapid processing of your request. Any information that is omitted may lead to a delay in processing your request. Once completed this form should be forwarded through the District TC/ PMO to your Regional Directorate, for them to discuss at the Regional Therapeutics Committee.

Medicine:

Form:

Strength:

Dose:

Duration of treatment

Action

.....

Why can currently available items not be used?

.....

.....

.....

Approximately how many patients will have this medicine each month?

What criteria will be used to determine which patients receive this medicine?

.....

.....

.....

Any other relevant information (please attach additional information to this form)

.....

.....

.....



TO BE COMPLETED BY PHARMACY DEPARTMENT

Supplier's name.....

Supplier's Contact Number

Cost per unit

Cost per patient

Cost implication per year

Requesting Officers signature:

Requesting Officers Name and Rank

(printed).....

PMO's/Medical Superintendent's signature:

District/Referral Hospital

TO BE COMPLETED BY REGIONAL THERAPEUTICS COMMITTEE

Date presented to Regional TC

Decision of Regional TC

.....

.....

.....

Request for Buy out Approved? YES NO

Duration Buy out approved for?

Regional Director's signature



NEMLIST

NAMIBIA ESSENTIAL MEDICINES LIST

SIXTH EDITION

FEBRUARY 2016



USAID
FROM THE AMERICAN PEOPLE

SIAPS 
Improved Access. Improved Services.
Better Health Outcomes.